Introduction {#s1}
============

Maintenance of fluid homeostasis is necessary for normal functions of the retina. Defects in supporting mechanisms result in macular edema that is the major cause of vision loss in common vascular and inﬂammatory diseases including diabetes, retinal vein occlusions and neovascularization affecting millions of people globally ([@bib7]). While vascular barrier disruption resulting in excessive leakage has been extensively studied, much less is known about the importance of fluid-removal mechanisms of neural retina that lacks lymphatic draining system.

The endothelial receptor tyrosine kinases Tie1 and Tie2 and the angiopoietin ligands (Angpt1--4) form a signaling pathway for blood and lymphatic vessel development ([@bib10]). Angiopoietin family studies thus far have focused on Angpt1 and Angpt2. As a significant limitation, the physiological importance of mouse Angpt4 (previously also named as Ang3 \[[@bib21]\], Angpt4 in accordance with the HUGO Gene Nomenclature Committee and Mouse Genome Informatics) and its human orthologue ANGPT4 ([@bib43]) have remained unknown. No gene-targeted model for Angpt4 has been published and ANGPT4 has not yet been linked to any human disease.

Thus far, controversial results regarding Angpt4 functions have been reported showing action as a Tie2 agonist or antagonist in vitro ([@bib20]; [@bib27]; [@bib43]). In mouse, excess of exogenous Angpt4 or ANGPT4 similarly induced blood and lymphatic vascular remodeling ([@bib22]; [@bib27]) and ANGPT4 improved vascular function in streptozotocin-induced model for diabetes ([@bib24]), suggesting that Angpt4, ANGPT4 and Angpt1 have similar functions. In mouse tumor transplantation studies, exogenous Angpt4 has been reported to either inhibit ([@bib51]) or promote tumor growth ([@bib4]; [@bib20]), and similarly to Angpt2, Angpt4 expression has been reported to increase in hypoxia ([@bib1]).

To clarify the physiological importance of Angpt4, we generated independently targeted mouse alleles to investigate cellular source, regulation of expression and the effect of Angpt4 deficiency in mouse retina that provides a widely used model for blood vessel growth, remodeling, maturation and vascular pathologies. In addition, *Angpt1* ([@bib28]), *Angpt2* ([@bib13])*, Tie1* ([@bib9]), and *Tie2* ([@bib5]) deletions are thoroughly investigated in postnatal mouse retina providing a comprehensive reference for assessing Angpt4 in vivo functions among the angiopoietins. Pathophysiological relevance of Angpt4 deficiency was evaluated in oxygen-induced retinopathy (OIR) model and using histopathological and ultrastructural analysis of postnatal and aged mice. Visual and venous functions were investigated using flash electroretinography and fluorescent tracers. We found Angpt4 expression in a specific population of hypoxia-regulated astrocytes that were enriched in the peripheral segment of the retina and locating close to the developing veins. Correlating with the strictly regulated expression pattern, genetic deletion of Angpt4 resulted in defective venous development and alterations in neural retina in adult mice secondary to impaired venous remodeling. Angpt4 deficiency did not affect capillaries or arteries either in physiological development, during aging or in retinopathy in OIR model, indicating a venous-specific function. Comparison of biochemical properties and cellular responses of Angpt4 and ANGPT4 to those of ANGPT1 and ANGPT2 provided novel mechanistic insights into the roles of Angpt4 and ANGPT4 and indicated both ligand-specific and redundant functions among the angiopoietins. Collectively, we identify Angpt4 as the first growth factor having a vessel-type-specific effect on venous development. Our data also reveals functional importance of a specific vein type in the peripheral retina, novel aspects of the complex Angpt/Tie pathway and complementary roles for angiopoietins in the establishment of the retinal circulatory system.

Results {#s2}
=======

Angpt4 is expressed in a distinct population of glial cells located close to the developing veins in the peripheral segment of postnatal mouse retina {#s2-1}
-----------------------------------------------------------------------------------------------------------------------------------------------------

In mice, the primary capillary plexus reaches the retinal periphery approximately at postnatal day (P) 8. Vascular remodeling and arteriovenous differentiation occur radially from the optic nerve head and different vessel types can be distinguished based on their morphology at P3 ([@bib6]; [@bib41]). To investigate Angpt4 expression and its physiological importance, we generated targeted *Angpt4*^LacZ^ and *Angpt4*^Cre^ mouse alleles and crossed *Angpt4*^Cre^ with a genetic fate mapping line *Rosa26*^mT/mG^ ([Figure 1---figure supplement 1A--C](#fig1s1){ref-type="fig"}). In whole mount retinal preparations, Angpt4 expressing cells were strongly enriched by P9 in *Angpt4*^LacZ^ mice ([Figure 1A](#fig1){ref-type="fig"}), at the time when peripheral venous maturation occurs ([@bib6]). At P20 ([Figure 1B](#fig1){ref-type="fig"}), when maturation of retinal vasculature is nearly completed, Angpt4 expressing cells were decreased in number and thereafter only few were observed close to the veins and perivenous capillaries. The same expression pattern was detected in *Angpt4*^Cre^*; Rosa26*^mT/mG^ mouse retina ([Figure 1C--G](#fig1){ref-type="fig"}), but not in controls ([Figure 1---figure supplement 2A--E](#fig1s2){ref-type="fig"}). During venous development, in both independent mouse lines, Angpt4 expressing cells were not randomly positioned but preferentially located in the peripheral segments while central retina was virtually negative ([Figure 1E](#fig1){ref-type="fig"} and [Figure 1---figure supplement 2C](#fig1s2){ref-type="fig"}).

![Angpt4 expression is temporally and spatially regulated at venous development sites in the peripheral retina.\
(**A--G**) Whole-mount retinas from *Angpt4*^LacZ^ and *Angpt4*^+/Cre^; *Rosa26*^mT/mG^ mice at the indicated postnatal days (P). (**A**) *Angpt4*^LacZ^ allele visualized with X-Gal staining (blue) indicated numerous Angpt4 expressing cells in the P9 peripheral retina at the sites of developing vein (V, asterisks) as identified based on anatomical location, morphology and reticulocytes. (**B**) *Angpt4*^LacZ^ allele revealed continued but lower Angpt4 expression (blue, arrows) around matured vein (V) in peripheral retina at P20. (**C**) In *Angpt4*^+/Cre^; *Rosa26*^mT/mG^ mice, mTomato (red) is ubiquitously expressed until *Angpt4*-promoter-driven Cre-mediated loxP recombination induces GFP (green) expression. P12 retina shows GFP-positive cells preferentially locating in the peripheral part of retina close to the branching vein (arrowheads). Arrow indicates rare single GFP-positive cells that are apart from vein (asterisks). Angpt4-expressing cells in *Angpt4*^+/Cre^; *Rosa26*^mT/mG^ mice are labeled permanently, that is they remain GFP positive even if Angpt4 expression is discontinued and may represent a progeny of Angpt4-expressing cells. (**D**) A schematic representation of mouse retina preparation. Peripheral venous circulation develops typically as two Y-shaped veins (thick arrows) starting after the first postnatal week and branching in the peripheral segment to form annular structure. Vein (V, blue line); artery (A, red line); OR, ora serrata; ON, optic nerve head; frame, location of microscopic analysis in [Figure 1](#fig1){ref-type="fig"} panels. (**E--G**) At P23 (late maturation phase), *Angpt4*^+/Cre^; *Rosa26*^mT/mG^ retina shows GFP-positive cells enriched in the peripheral segment when compared to the central retina. Magnifications (**F**) and (**G**) reveal a GFP-positive cell population (arrowheads) connected to veins and perivenous capillaries.](elife-37776-fig1){#fig1}

Based on their morphology, position in the superficial retinal layer, and specific cell marker gene (GFAP) expression, we identified Angpt4 expressing cells as astrocytes ([Figure 2A--D](#fig2){ref-type="fig"}). During the postnatal development, vasculature is expanded and perfused from the optic nerve head towards the peripheral retina creating an oxygen gradient resembling Angpt4 expression pattern. In addition, Angpt4^+^ astrocytes were less numerous close to arteries ([Figure 2A--B](#fig2){ref-type="fig"}) where oxygen tension is higher than in veins. To confirm that low oxygen level positively regulates Angpt4 expression, *Angpt4*^Cre/+^; *Rosa26*^mT/mG^ mice were exposed to low oxygen atmosphere ([Figure 2E--G](#fig2){ref-type="fig"}) and retinal ischemia (OIR model, [Figure 2---figure supplement 1A--E](#fig2s1){ref-type="fig"}) that both increased the number of Angpt4^+^ astrocytes. By using conditional genetic depletion, we further confirmed that Angpt4 expression is positively regulated by HIF prolyl-hydroxylase 2 (Egln1) -dependent hypoxia pathway ([Figure 2H](#fig2){ref-type="fig"}). In hyperoxia, which in short-term promotes astrocyte differentiation ([@bib8]), in long-term causes retinal degeneration ([@bib52]) and paradoxically can cause hypoxia by blocking vascular development in the retina ([@bib50]), *Angpt1* mRNA expression was decreased while *Angpt2* and *Angpt4* mRNA levels increased. In addition, there was a trend for increased number of *Angpt4*^+^ astrocytes ([Figure 2---figure supplement 2A--C](#fig2s2){ref-type="fig"}).

![Angpt4 marks a specific subpopulation of retinal astrocytes and is induced in low oxygen.\
Angpt4 lineage cells (GFP, green) visualized in *Angpt4*^Cre/+^; *Rosa26*^mT/mG^ reporter mice in adult (2 months) in (**A-D**) retina. Angpt4-negative cells express mTomato (red). (**A**) Similarly to developing retina ([Figure 1](#fig1){ref-type="fig"}), GFP-positive cells are enriched in the distal segment near ora serrata (OR) when compared to central retina. GFP positive cells are also less numbered near to arteries (A, arrowheads) than veins (V, arrows). Quantification of the image data is shown in (**B**). (**C**) Section through the adult retina (R) reveals Angpt4 lineage cells (arrowheads) locating in the superficial layer of retina, whereas other retina layers are negative (VB, vitreous body; IPL, inner plexiform layer; INL, inner nuclear layer; ONL, outer nuclear layer; C, choroid). (**D**) All GFP^+^ cells (arrowhead) express astrocyte marker GFAP (white). However, not all astrocytes are GFP positive (arrow). (**E--G**) Low oxygen increases number of Angpt4^+^ astrocytes, but does not induce Angpt4 expression in other cell types (in 1.5 months old mice). Quantification of the image data is shown in (**G**). (**H**) Induction of hypoxia-inducible factor pathway in Angpt4-expressing cells via *Angpt4*^Cre^ mediated *Egln1* deletion increases *Angpt4* expression in P12 eye. Mean ±SD, \*\*p\<0.01 in t-test. *n* = 5 (**B**) and *n* = 4 mice (**G**)/group. In (**H**) *n* = 5 *Egln1*^loxP/loxP^ and *n* = 2 *Angpt4*^Cre^; *Egln1*^loxP/loxP^ mice.](elife-37776-fig2){#fig2}

To investigate in detail when Angpt4 expression initiates and to compare Angpt4 expression pattern to Angpt1, Angpt2 and Tie2 especially in the peripheral retina, we performed in situ hybridization of antisense RNA probes on postnatal retina whole mounts ([Figure 3A--E](#fig3){ref-type="fig"}). At P2, one retina out of four showed a few Angpt4 expressing cells. At P3, *Angpt4* in situ signal was found consistently and it preceded the growing vascular front ([Figure 3A](#fig3){ref-type="fig"}). At P12, *Angpt4* mRNA was enriched in the astrocytes in the peripheral retina ([Figure 3B](#fig3){ref-type="fig"}), while no specific staining was detected in *Angpt4^-/-^* retina ([Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}). In situ hybridization thus confirmed the expression data obtained from *Angpt4*^Cre^ and *Angpt4*^LacZ^ models, but also revealed a few more *Angpt4^+^*cells than observed in the genetic models, possibly due to better sensitivity. In the peripheral retina, *Angpt1* mRNA was not detectable at P12 ([Figure 3C](#fig3){ref-type="fig"}), while *Angpt2* mRNA was found to be expressed in neuron cells in the intermediate layers of retina ([Figure 3D](#fig3){ref-type="fig"}) as reported earlier ([@bib15]). *Tie2* mRNA was localized in ECs in veins, arteries and capillaries ([Figure 3E](#fig3){ref-type="fig"}). Corresponding sense probes were used as controls ([Figure 3---figure supplement 1B--F](#fig3s1){ref-type="fig"}) and *Angpt1* antisense probe was validated by positive signal from P4 retina and P2 atriums ([Figure 3---figure supplement 1G--J](#fig3s1){ref-type="fig"}), as expected based on published expression data of Angpt1-GFP ([@bib23]; [@bib33]).

![mRNA expression of angiopoietins and *Tie2* in retinal vein development.\
mRNA expression was detected in whole mount retinas from WT mice by in situ hybridization. (**A**) At P3, astrocytes expressing *Angpt4* precede the front of the developing vasculature (red blood cells indicated by arrows). (**B**) At P12, *Angpt4* expression is notable around the developing vein in the peripheral retina (V, asterisks) and colocalizes with the astrocyte marker GFAP (white overlay in insert). (**C**) *Angpt1* expression is not detected at P12 by whole mount in situ hybridization in the peripheral retina. (**D**) *Angpt2* is expressed in retinal neurons (arrowhead) in the intermediate retinal plexus. (**E**) Expression of *Tie2* is detected in the endothelium of arteries (A), veins and capillaries at P12. OR, ora serrata.](elife-37776-fig3){#fig3}

Angpt4 deficiency results in defective venous development in the peripheral retina {#s2-2}
----------------------------------------------------------------------------------

RT-qPCR confirmed the lack of *Angpt4* mRNA in *Angpt4*^Cre/Cre^ mice (hereafter *Angpt4*^-/-^) and no compensatory change in *Angpt1* or *Angpt2* was detected ([Figure 1---figure supplement 1D](#fig1s1){ref-type="fig"}). As a first implication of a vascular phenotype, we observed weak alpha smooth muscle actin (αSMA) immunofluorescence in *Angpt4*^-/-^ SMCs around the forming veins in the peripheral part of the retina at P12 ([Figure 4A--B](#fig4){ref-type="fig"}), correlating well with the spatiotemporal Angpt4 expression pattern. The low αSMA expression defect around veins persisted into adulthood ([Figure 4C--F](#fig4){ref-type="fig"}). Furthermore, the diameter of peripheral veins did not increase during development ([Figure 4J--K](#fig4){ref-type="fig"}). In both P12 and adult mice, the defective vascular morphogenesis was observed in the veins and preferentially in those locating at retina\'s periphery but not in central retina close to the optic nerve head ([Figure 4G--H,J--K](#fig4){ref-type="fig"}). In addition, arteries, peripheral arterioles and capillaries remained unaffected ([Figure 4C--F,I](#fig4){ref-type="fig"}) and no consistent alterations were observed in the vasculature of the intermediate or deep vascular plexuses postnatally or in adults ([Figure 4---figure supplement 1A--I](#fig4s1){ref-type="fig"}).

![Retinal veins of Angpt4 deficient mice show SMC abnormality and smaller diameter.\
(**A**) P12 WT retina whole mount shows strong αSMA staining (red, arrows) in the developing annular vein in the peripheral retina. (**B**) αSMA staining is weak in *Angpt4*^-/-^ retina especially in the peripheral location (red, arrows). Asterisks indicate developing Y-shaped annular peripheral vein in (**A**) and (**B**). (**C--F**) Whole mount retinal staining of nine months old mice. αSMA staining (red) (**C, E**) and merged image (**D, F**) with Col IV (green) indicate perivascular sleeves. In *Angpt4*^-/-^ retina, αSMA level is low around annular veins (V, arrows) in the peripheral retina, but not around arteries (A). (**G--I**) αSMA immunofluorescence intensity (IF) in *Angpt4*^-/-^ retina is reduced around annular peripheral veins (**G**), but not in veins close to optic nerve head (central) (**H**) or arteries (**I**) (*n* = 3 mice/group). (**J--K**) Peripheral annular vein diameter is reduced in *Angpt4*^-/-^ retina. *n* = 8 WT and 6 *Angpt4*^-/-^ mice, measured from the base of the peripheral bifurcation (**J**). *n* = 8 WT and 8 *Angpt4*^-/-^ mice, measured from the central region close the optic nerve head (**K**). Mean ±SD, \*\*\*p\<0.001 in t-test.](elife-37776-fig4){#fig4}

In WT mice, vein SMCs gradually acquire a matured phenotype characterized by increased cytoskeletal myofilaments and deposition of fibrillar collagen matrix evident in ultrastructural examination by transmission electron microscopy (TEM). Based on TEM, immature SMCs were present in the peripheral veins at P8 ([Figure 5A](#fig5){ref-type="fig"}). At later time points, however, ultrastructural analysis revealed lack of cellular and molecular characteristics of matured SMCs in *Angpt4*^-/-^ mice ([Figure 5B--F,M--N](#fig5){ref-type="fig"}). To confirm defective maturation, whole mount retinas were stained for SM22, a marker of adult SMCs ([@bib29]), which was greatly reduced around *Angpt4*^-/-^ veins ([Figure 5G--J](#fig5){ref-type="fig"}). Together with diminished αSMA and ultrastructural findings, this data indicated that Angpt4 is needed for SMC maturation. In vitro, angiopoietin receptor TIE2 was expressed predominantly in human ECs, but also in SMCs isolated from adult human veins or arteries ([Figure 5K](#fig5){ref-type="fig"}). Excess of ANGPT4, however, did not increase SMC survival in Caspase 3/7 ELISA and did not promote SMC migration in scratch assay or their proliferation in BrdU ELISA ([Figure 5---figure supplement 1A--C](#fig5s1){ref-type="fig"}). qPCR from retinas did not reveal statistically significant changes in factors previously implicated in venous development, except a decrease in *Tie2* ([Figure 5L](#fig5){ref-type="fig"}). Collectively, these experiments indicated that Angpt4 is required for SMC maturation, but not for SMC recruitment, proliferation or survival and that Angpt4 does not directly signal to SMCs.

![Angpt4 deficiency results in defective SMC maturation in veins.\
TEM micrographs of peripheral annular vein in P8 (**A**) and adult (11 months old) mice (**B**). SMCs are marked by red line. In the developing veins, SMCs are covered by basement membranes (BM, arrowheads) and SMC cytoskeleton appears translucent with some myofilaments (arrow). Perivascular ECM contains no fibrillar collagen. In adult mouse, venous SMC cytoplasm is mostly filled with myofilaments and perivascular matrix contains fibrillar collagen (Col). TEM micrographs of peripheral vein in 2 (**C, D**) and 11 (**E, F**) months old WT and *Angpt4*^-/-^ mice, respectively. In both genotypes, perivascular cells (red line) are closely aligned with ECs and surrounded by BM (arrowheads) that indicates SMC identity. In *Angpt4*^-/-^ retina, SMC cytoplasm lacks myofibril-rich cytoskeleton and fibrillar collagen (Col) matrix. No ultrastructural abnormalities are observed in ECs. (**G--J**) Whole mount retinal staining of peripheral veins in 2 months old WT (**G, I**) and *Angpt4*^-/-^ (**H, J**) mice. SM22 (red) (**G--J**) and IB4 (green) (**G, H**) staining. In *Angpt4*^-/-^ retina, SM22 level is low around veins (arrows, V). (**K**) Tie2 expression in arterial (a) and venous (v) SMC cell lines. HUVECs and fibroblasts are positive and negative controls, respectively. (**L**) qPCR analysis of venous specification marker genes at P12 retinas (*Angpt4^-/-^n* = 5 and WT *n* = 6). (**M--N**) Quantification of SMC maturation markers from TEM analyzed retinas (*n* = 6 WT and *n* = 7 *Angpt4*^-/-^ mice). (**O**) Peripheral annular vein diameter is reduced in *Angpt4*^-/-^ retina (*n* = 7 mice/group, the shortest diameter of peripheral branch measured from TEM cross-section). Data are presented as mean ±SD, \*\*\*p\<0.001 and \*\*p\<0.01 *Angpt4*^-/-^ vs. WT in t-test.](elife-37776-fig5){#fig5}

Angpt4 deficiency results in neuronal cell alterations in the inner nuclear layer of the retina {#s2-3}
-----------------------------------------------------------------------------------------------

Instead of a single common disease mechanism, neuronal edema is a complicated condition that results from multiple and still incompletely understood defects in fluid homeostasis caused by excessive fluid entry and/or insufficient clearance. In the retina, the transudate ﬂuid is proposed to be absorbed back either into venous circulation, vitreous or choroid ([@bib7]). A model, in which one route is specially defective, should be particularly informative to study the importance of a putative ﬂuid drainage mechanism. To evaluate the respective role of venous drainage, we investigated possible histological and ultrastructural changes in *Angpt4*^-/-^ mice. Based on a laser photocoagulation induced mouse model for vein occlusion, edema is located mainly in the inner nuclear layer (INL) of the retina ([@bib12]). Therefore, we focused our histological analysis to INL, which is separated from the superficial vascular layer only by \~50 µm in mouse. In light microscopy, the thickness of the INL was increased in adult *Angpt4*^-/-^ retinas ([Figure 6A--B](#fig6){ref-type="fig"}). TEM revealed enlarged, cell-organelle-free cytoplasm in neuronal cell somas in adult INL ([Figure 6D](#fig6){ref-type="fig"}), a phenotype that closely resembled ultrastructural changes of swollen cells ([@bib30]). In addition, the normal architecture of Müller cells that have a specialized function in retinal ﬂuid management expressing specific channels for water efflux ([@bib40]) was lost around the swollen cell bodies. These changes were not seen in P13 mice ([Figure 6C](#fig6){ref-type="fig"}). In adult mice, however, we found no alterations in the expression of AQP4 water (1.0 ± 0.2 vs.1.9 ± 1.5) or Kir4.1 potassium channels (1.0 ± 0.1 vs. 1.1 ± 0.3) (WT vs. *Angpt4*^-/-^, mean ±SD, WT value set to 1, *n* = 3 in both genotypes, p=NS in t-test). Comparison of P13 and adult mice revealed that changes in neuronal cells occurred after defective venous development ([Figure 6C--D](#fig6){ref-type="fig"}) and were not found in other retinal layers than in INL ([Figure 6---figure supplement 1A--D](#fig6s1){ref-type="fig"}). We observed no evidence of cystoid edema or inflammation (lack of fluid-filled cysts and cellular infiltration in histology in [Figure 6A--B](#fig6){ref-type="fig"} and in ultrastructure in [Figure 6---figure supplement 1A--D](#fig6s1){ref-type="fig"}, and no increase in general inflammation markers in [Figure 6---figure supplement 2A--B](#fig6s2){ref-type="fig"}).

![Neuronal cell swelling in adult *Angpt4^-/-^* mice.\
(**A--B**) Light microscopy images of peripheral retinal sections from control and *Angpt4*^-/-^ mice stained with (**A**) toluidine blue (*n* = 7 mice/group) or (**B**) Masson\'s trichrome (*n* = 9 control and 5 *Angpt4*^-/-^ mice). Framed area of inner nuclear layer (INL) is magnified on the right. Two different fixation, embedding and staining protocols indicate increased thickness of the INL in (**A**) and (**B**), data analyzed at least from four sections per mouse. (**C--D**) TEM micrographs from peripheral INL. (**C**) *n* = 8 control and 6 *Angpt4*^-/-^ P13 mice and in adult mice (**D**) *n* = 8 control and 8 adult *Angpt4*^-/-^ mice. Quantification (on the right) was done from cell somas locating in the interface between INL and inner plexiform layer that is composed mainly of amacrine cells ([@bib18]). Asterisks indicate cell swelling in (**D**) and black arrows Müller cell processes (**C, D**) that are displaced around swollen cells. A, amacrine cell; M, Müller glia; B, bipolar cell. (**A--D**) Median (line), average (square), 75th quartile (box), 5th and 95th percentile (whiskers) in whisker blots. \*p\<0.05 and \*\*p\<0.01 WT vs. *Angpt4*^-/-^ in t-test. \
10.7554/eLife.37776.017Figure 6---source data 1.Cell soma areas of individual neuronal cells in the interphase between INL and IPL.](elife-37776-fig6){#fig6}

Decreased venous drainage and neuronal activity in *Angpt4*^-/-^ retinas {#s2-4}
------------------------------------------------------------------------

We next investigated possible functional changes in venous flow and neuronal activity. Fluorescein angiography (FA) was used to investigate blood circulation and vascular leakage, and flash electroretinography (fERG) to evaluate neural retinal function. In FA, sodium fluorescein was injected intraperitoneally and the entering of fluorescent tracer to the retinal circulation was followed by video recording. In the early phase, venous filling in relation to arteries was decreased in *Angpt4*^-/-^ mice ([Figure 7A,C,E](#fig7){ref-type="fig"}). No leakage was observed in the peak phase of fluorescence ([Figure 7B,D](#fig7){ref-type="fig"}). Limitation in fundus camera imaging is that the far peripheral retina is not fully visible; therefore, in addition to FA, we further investigated venous function in the peripheral location in whole-mount preparations after injection of fluorescent spheres into carotid artery. In *Angpt4*^-/-^ mice, retention of fluorospheres was evident in the peripheral annular vein bifurcation sites, suggesting slower draining time than in controls ([Figure 7F--H](#fig7){ref-type="fig"}). In aged (eight mo) *Angpt4^-/-^* mice, fERG demonstrated a decrease in b-wave amplitude that measures the activity of the bipolar, Müller and amacrine cells ([Figure 7I](#fig7){ref-type="fig"}). In contrast, a-wave amplitude, generated by photoreceptors, was not affected ([Figure 7---source data 1](#fig7sdata1){ref-type="supplementary-material"}). We found no evidence for vascular leakage in fluorescein angiography ([Figure 7D](#fig7){ref-type="fig"}) or hypoxia (negative pimonidazole staining and mRNA markers in [Figure 7---figure supplement 1A--D](#fig7s1){ref-type="fig"}).

![Functional analysis of venous flow and neuronal activity in retina.\
(**A-D**) Filling of the retinal veins in fluorescein angiography. Fundus camera images show the same retinas in (**A**) and (**B**) and in (**C**) and (**D**) in early filling phase (**A, C**) and in the peak phase of fluorescence (**B, D**). Arrowheads highlight examples of veins extending peripheral retina. (**E**) Quantification of the early filling image data; symbols represent fluorescein intensity in individual veins/average arterial fluorescein intensity in the same eye from 7 WT and 5 *Angpt4-*deficient mice. (**F--G**) Retention of fluorospheres in the peripheral annular vein after carotid artery injection. Blood vessels were counterstained with Cy3-conjugated αSMA antibody and co-injected Evans blue. (**H**) Two different sphere concentrations were used, and results are expressed as number of microspheres normalized by the length of venous segment analyzed. Each symbol represents an individual vein from 5 WT and 5 *Angpt4-*deficient mice. (**I**) Amplitudes of the b-wave in aged (eight months) WT and *Angpt4* deficient mice. ERGs were measured at six different flash intensities as indicated. Data are presented as mean ±SD (*n* = 12 WT and *n* = 8 *Angpt4*^-/-^ eyes). \*\*p\<0.01, \*p\<0.05 in t-test.\
10.7554/eLife.37776.020Figure 7---source data 1.Electroretinogram measurements of individual eyes.](elife-37776-fig7){#fig7}

Angpt4 and ANGPT4 expand endothelial lumen structure via the TIE2/PI3K/serine protease pathway {#s2-5}
----------------------------------------------------------------------------------------------

In addition to defective SMC maturation, luminal diameter was smaller in *Angpt4*^-/-^ veins measured from retina whole mounts ([Figure 4J--K](#fig4){ref-type="fig"}) and TEM sections ([Figure 5O](#fig5){ref-type="fig"}), indicating halted venous development. To investigate molecular pathways via which Angpt4 may induce expansion of the endothelial luminal structure, human umbilical vein endothelial cell (HUVEC) spheroids were stimulated with Angpt4 and ANGPT4 in the fibrin gel model. Using inhibitors against plasmin/serine proteases (aprotinin), PI3K (BYL719 and LY294002) and shRNA constructs directed against TIE2 ([Figure 8A--D](#fig8){ref-type="fig"}), we found that similarly to ANGPT1, Angpt4 and ANGPT4 induced growth of luminal structures TIE2, PI3K and serine protease dependently. In a co-culture spheroid model, ANGPT4-induced lumen enlargement was not enhanced by SMCs ([Figure 8---figure supplement 1A](#fig8s1){ref-type="fig"}) and SMC spheroids alone did not respond to ANGPT4 ([Figure 8---figure supplement 1B](#fig8s1){ref-type="fig"}).

![Angpt4 and ANGPT4 expand endothelial lumen structure via TIE2/PI3K/serine protease pathway.\
In vitro studies were performed by using mouse Angpt4 and human ANGPT4 purified recombinant proteins. (**A**) Lumen formation in HUVEC spheroids in fibrin gel angiogenesis model. Spheroids were stimulated with indicated recombinant (r) or virally produced (v) angiopoietins in the presence or absence of inhibitors indicated. Median (line), average (square), 75th quartile (box), 5th and 95th percentile (whiskers), outliers (•). \*\*p\<0.01, \*p\<0.05 stimulation vs. control, ^§§§^p\<0.001, ^§§^p\<0.01 and ^§^p\<0.05 inhibitor vs. no inhibitor in Kruskal--Wallis non-parametric ANOVA followed by Mann--Whitney U-test, *n* = 3 to 12 experiments. (**B**) Representative images of spheroids stimulated with angiopoietins and in the presence of inhibitors. (**C**) Lumen area in control or lentiviral TIE2 shRNA construct (412 or 413) treated HUVEC spheroids. Area of control shRNA lumen was set to 1. (**D**) Representative images of shRNA-treated spheroids.](elife-37776-fig8){#fig8}

Angpt4 and ANGPT4 show both ligand-specific and redundant functions among the angiopoietin family {#s2-6}
-------------------------------------------------------------------------------------------------

The observed phenotype in *Angpt4*^-/-^ retinas was clearly different from that observed in mice lacking Angpt1 ([@bib28]) or Angpt2 ([@bib13]; [@bib16]) that both result in reduced growth of primary capillary plexus and not in vein-specific phenotype. In addition, in OIR model, *Angpt1* ([@bib28]) and *Angpt2* ([@bib16]) deletions reduce neovascular tuft formation, while Angpt4 deficiency has no such effect ([Figure 2---figure supplement 1A--E](#fig2s1){ref-type="fig"}). To investigate if different vascular phenotypes may reflect differential molecular and cellular characteristics between the ligands, we next compared angiopoietins in in vitro assays ([Figure 9A--H](#fig9){ref-type="fig"}). ANGPT1 induces TIE2 translocation and phosphorylation in EC--EC junctions to activate Akt signaling in confluent ECs that increases endothelial stability ([@bib11]; [@bib37]). Similarly to ANGPT1, but opposite to ANGPT2, Angpt4 and ANGPT4 induced TIE2 phosphorylation in inter-endothelial junctions ([Figure 9A--B](#fig9){ref-type="fig"}). In sparse migrating ([@bib11]; [@bib37]) and spreading ECs ([@bib34]), ANGPT1 and ANGPT2 induce TIE2 translocation to specific ECM contact sites to regulate EC adhesion and migration. In contrast to ANGPT1 and ANGPT2, Angpt4 and ANGPT4 did not bind to EC ECM ([Figure 9D](#fig9){ref-type="fig"}). After prolonged stimulation, the majority of ANGPT1-bound TIE2 is translocated into retraction fibers that represent former EC-ECM adhesions. Interestingly, ANGPT2/TIE2 was mainly located in the cell rear and not incorporated into permanent EC-ECM contacts, while ANGPT4 did not induce TIE2 translocation to ECM contacts to a significant extent ([Figure 9C](#fig9){ref-type="fig"}). When substrate-bound by solid phase antibody, Angpt4 and ANGPT4 failed to promote EC spreading that was induced by substrate-bound ANGPT1 ([Figure 9E--F](#fig9){ref-type="fig"}). To test if differences in adhesion are related to differential binding characteristics to TIE2, angiopoietins were compared in ELISA and surface plasmon resonance (SPR) assays ([Figure 9G--H](#fig9){ref-type="fig"}). In both assays, Angpt4 and ANGPT4 showed lower affinity to TIE2 than ANGPT1 and ANGPT2. We further evaluated the diffusion and kinetics of the ANGPT/TIE2-GFP complexes by the fluorescence recovery after photobleaching (FRAP) method ([Figure 9---figure supplement 1A--C](#fig9s1){ref-type="fig"}). Among the ligands, recovery rate was highest in Angpt4- and ANGPT4-stimulated cells, whereas ANGPT1 stimulation resulted in slowest recovery. Collectively, in vitro characterization indicated that similarly to ANGPT1, Angpt4 and ANGPT4 activated TIE2 in EC--EC junctions. When compared to other angiopoietins, binding to TIE2 and EC ECM was weaker, likely resulting in less stable ligand/TIE2 complexes evident in FRAP and prolonged stimulation experiments. To further compare biochemical characteristics of angiopoietins used in this study, purified recombinant proteins were analyzed by SDS polyacrylamide gel electrophoresis and their potency to induce TIE2 tyrosine phosphorylation (activation) was quantified by immunoprecipitation and western blotting ([Figure 9---figure supplement 2A--D](#fig9s2){ref-type="fig"}). As previously published ([@bib27]; [@bib43]), ANGPT4 induced TIE2 tyrosine phosphorylation in HUVECs. In comparison, Angpt4 was less oligomerized ([Figure 9---figure supplement 2C--D](#fig9s2){ref-type="fig"}) and induced relatively low TIE2 activation in human ECs when total TIE2 proteins were analyzed in western blot ([Figure 9---figure supplement 2A--B](#fig9s2){ref-type="fig"}). This was consistent with immunostaining ([Figure 9A](#fig9){ref-type="fig"}) of Angpt4-stimulated HUVECs, where TIE2 activation was observed as punctuate staining specially locating in EC-EC junctions, while a vast majority of TIE2 was evenly located on plasma membrane and was not stained with antibody specific for phosphorylated TIE2-Tyr992 on the kinase activation loop ([@bib32]).

![Ligand-specific and redundant functions of Angpt4 and ANGPT4.\
(**A**) Angiopoietin-induced TIE2 translocation and activation in cell--cell junctions. TIE2-WT HUVECs were left non-stimulated (control) or stimulated with recombinant angiopoietins as indicated for 1 hr, fixed, and stained for total TIE2 (green), phosphorylated TIE2 (pTIE2, red) and nuclei (DAPI, blue). White cropping indicates examples of ROIs (sites where cell contacts occurred based on microscopic examination) for TIE2 and pTIE2 intensity measurement from randomly selected cells. (**B**) Quantification of TIE2 activation (pTIE2/total TIE2) in cell--cell junctions (*n* = 2 to 7 stimulations, total 330 to 915 cell junctions/stimulation were measured). (**C**) Sparse TIE2-GFP HUVECs were stimulated with angiopoietins overnight, fixed and imaged. In ANGPT1-stimulated cells, majority of TIE2-GFP is ECM bound (arrows). ANGPT2 promoted TIE2 translocation to the retracting cell edges (arrows) and less in ECM (dotted line indicates leading edge of the cell). Angpt4 and ANGPT4 did not induce long-term effect on TIE2 clustering and translocation into ECM. (**D**) Angiopoietin binding to acellularized ECM fraction from cultured HUVECs (*n* = 4 run in triplicate). (**E**) TIE2-WT HUVECs spreading on fibronectin, ANGPT1, ANGPT2, Angpt4 or ANGPT4. Cells were let to spread on coated coverslips for 1 hr and stained for actin. Quantification of image data is shown in (**F**). Cell area was normalized to fibronectin (FN) (*n* = 3 to 9 experiments, 333 to 1778 cells per coating were analyzed). (**G**) Angiopoietin-TIE2 binding affinity measured by ELISA. ANGPT1 binding to TIE2 (250 ng/ml) was set to one at ANGPT1 concentration 500 ng/ml (*n* = 4 experiments). (**H**) Angiopoietin binding to TIE2 in surface plasmon resonance assay. Human purified TIE2-Fc was immobilized on CM5 chip, and angiopoietins were injected onto the TIE2-Fc surface at 100 nM concentration. Mean ±SD, ANOVA followed by the Bonferroni post hoc test. \*\*\*p\<0.001, \*\*p\<0.01, \*p\<0.05 vs. control; ^†††^p\<0.001, ^††^p\<0.01 vs. ANGPT1; ^\#\#\#^p\<0.001, ^\#\#^p\<0.01, ^\#^p\<0.05 vs. ANGPT2.](elife-37776-fig9){#fig9}

Angpt4 expression outside of retina {#s2-7}
-----------------------------------

As the neural retina can be considered as a part of central nervous system, we were interested in whether Angpt4 expressing astrocytes are also present in the brains. To support this suggestion, in a previous study ANGPT4 protein was reported to be expressed in normal, unselected population of human astrocytes at low level and increased in human glioma ([@bib4]). However, in primary astrocyte cultures from WT mice ([Figure 10---figure supplement 1A](#fig10s1){ref-type="fig"}) or in *Angpt4*^Cre^; *Rosa26*^mTmG^ brains (data not shown) we found no Angpt4 expression in astrocytes. To explore Angpt4 expression outside of the vasculature of the central nervous system, we analyzed mesenteric whole*-*mounts, where vasculature is readily visible for microscopic analysis. Interestingly, Angpt4 expression was found in arterial SMCs ([Figure 10](#fig10){ref-type="fig"}). To investigate the presence of circulating Angpt4, serum samples and the non-cellular supernatant of the eye that contained retinal extracellular soluble proteins and vitreous constituents were collected from WT and *Angpt4* deficient mice at P12. ELISA did not detect Angpt4 in mouse serum and quantity of soluble Angpt4 was low in the eye preparations indicating that there is no significant amount of circulating Angpt4 ([Figure 10---figure supplement 1B](#fig10s1){ref-type="fig"}).

![Outside of retina, *Angpt4* is expressed in muscular arteries in adult mice.\
(**A**) LacZ gene negative control. (**B--C**) Whole mount preparations of small intestine mesentery showed X-gal staining in *Angpt4*^LacZ^ mice arteries, but not in veins. (**D**) TEM analysis of *Angpt4*^LacZ^ mesentery artery showed X-gal staining as electron-dense precipitation (arrows) inside arterial smooth muscle cell (aSMC) in tunica media layer, whereas the ECs and SMCs in LacZ gene negative control (insert) did not contain precipitate. Lu, vessel lumen. (**E**) X-gal staining in tunica media layer (bracket) in the cross section of *Angpt4*^LacZ^ mesenteric artery. (**F**) Cross-section of mesenteric artery from negative control *Angpt4*^+/+^; *Rosa*26^mTmG^. Elastin shows green autofluorescence. (**G**) *Angpt4*^Cre^; *Rosa*26^mTmG^ fate mapping mouse line showed GFP signal in tunica media layer (bracket), whereas ECs were negative.](elife-37776-fig10){#fig10}

Discussion {#s3}
==========

In this study, we show that Angpt4 is necessary for venous remodeling and SMC maturation in the mouse retina. Lack of known growth factor(s) to initiate venous specification has hindered understanding the determination of venous fate, and therefore it is often considered as a default. Vascular SMCs are heterogenic cells that arise from multiple different origins in development ([@bib48]). In the retina, vein SMCs can develop from neural crest origin ([@bib17]; [@bib42]); however, thus far the molecular pathway(s) needed to initiate maturation of venous SMCs has been unknown. Our study identifies Angpt4 as the first growth factor having a venous-specific function in the mouse retina, thus providing new insights into poorly characterized developmental processes. From a translational perspective, identification of new molecules that regulate the formation of functional vasculature in the eye is necessary for the development of novel therapies that can have a major impact on the treatment of patients with limited treatment options. More broadly, understanding the mechanisms to establish an efficient circulatory loop involving functional veins is also crucial for development of regenerative medicine in general. Main findings and the mechanisms involved in the phenotypes observed in this study are presented in a graphical summary ([Figure 11](#fig11){ref-type="fig"}).

![Graphical summary.\
(**A**) Whole mount staining of the superficial vascular plexus of adult mouse retina, one quarter is shown. In mouse, typically two large veins extend to the far periphery of the retina to form an annular vessel structure (arrows), where peripheral capillaries drain. A, artery; V, vein; ON, optic nerve head. Framed area is represented in (**B**) and (**C**). (**B**) Angpt4 is expressed in a specific subpopulation of hypoxia-regulated astrocytes that are enriched in the peripheral retina and locate close to the developing veins to promote venous remodeling and SMC maturation via endothelial cell-expressed Tie2. Potential fluid removal mechanisms from neural retina include retinal pigment epithelial (RPE) cell pumps, venous drainage and diffusion to vitreous ([@bib7]). (**C**) Angpt4 deficiency leads to defective circumferential growth and SMC maturation in early postnatal development that secondarily leads to neuronal cell damage due to impaired venous drainage. Tie2 signaling has a special importance in venous development ([@bib5]; [@bib46]), and in the peripheral retina, expression of competitive Angpt1 ligand is low that may contribute to the localized, vessel-type specific phenotype in Angpt4 deficient mice.](elife-37776-fig11){#fig11}

Mouse retinal vasculature develops postnatally in a highly organized and reproducible pattern. Formation of astrocyte network in the superficial retinal layer occurs between embryonic day 19 and first postnatal day thus preceding vascular development. Astrocytes have a special function to form a template for sprouting ECs, and together with retinal ganglion cells astrocytes express growth factors for angiogenic guidance and EC survival ([@bib39]). Interestingly, astrocytes are known to be a heterogeneous cell population ([@bib3]) and our data indicates that Angpt4^+^ astrocytes represent a specific subpopulation among the glial cells. Intriguingly, genetic deletion revealed that Angpt4 is especially important in the far peripheral segment that may develop via different pathway than central neural retina ([@bib45]). In addition, clinical wide-field fundus imaging has identified a number of vascular diseases in humans in the peripheral retina that can affect also macula even though primary defect is peripheral ([@bib2]; [@bib49]). Despite its emerged clinical importance, until now no mechanism specially regulating vascular remodeling in this domain has been described.

Angpt4 expression was not found in mouse brain astrocytes, which further strengthens our conclusion that Angpt4^+^ astrocytes represent a specific subpopulation. Outside of retina, we found *Angpt4* expression in arterial SMCs. These results (negative brain astrocytes, expression in certain SMCs) are in line with a recent comprehensive single-cell transcriptomic study of the mouse brain vasculature ([@bib44]). Interestingly, in addition to retinal neuronal cells, Angpt1-GFP is also reported to be expressed in perivascular mural cells ([@bib33]). The data is currently limited but suggests that both Angpt1 and Angpt4 can be expressed in certain vascular SMCs, raising interesting questions regarding ligand-specific and possible synergistic or additional effects of these Tie2 ligands. Binding affinity of purified recombinant ANGPT4 protein to TIE2-Fc was considerably low when compared to ANGPT1 that binds TIE2 with high affinity. Nevertheless, ANGPT4 to TIE2 binding was sufficient for TIE2 phosphorylation (activation) in cell culture assays. In the case both ligands are present, the higher affinity may favor ANGPT1/TIE2 binding in tissues. Originally, ANGPT4 was identified as a TIE2 agonistic ligand in HUVECs ([@bib27]; [@bib43]). In the first reports, mouse Angpt4 did not significantly induce TIE2 phosphorylation in human ECs when analyzed in western blot that suggested a species-specific effect ([@bib27]; [@bib43]). However, in mice, excess of both Angpt4 and ANGPT4 similarly induced angiogenic remodeling in corneal micropocket assay ([@bib27]) and in the trachea ([@bib22]), indicating that Angpt4 and ANGPT4 have similar in vivo functions. In our study, Angpt4 promoted lumen formation of human ECs with somewhat lower extent, but we observed no differences in Angpt4 and ANGPT4 binding characteristics to ECM, ECs or TIE2. Collectively, this suggests that despite relatively low average sequence homology (65% identity) between Angpt4 and ANGPT4, certain functional characteristics are still conserved.

Interestingly, observed spatiotemporally regulated expression of Angpt4 in astrocytes in the peripheral retina close to the developing veins significantly differed from other angiopoietins ([@bib13]; [@bib15]; [@bib16]; [@bib33]). In addition, the venous-specific phenotype we characterize in *Angpt4^-/-^* mice also differs from defects in *Angpt1^-/-^* and *Angpt2^-/-^* retinas; *Angpt1* deletion at P2--4 (analyzed at P5) caused reduced vascular density ([@bib28]), and *Angpt2* deficiency decreased sprouting of the primary plexus and delayed regression of the embryonic hyaloid vasculature at P10 ([@bib13]). Although Angpt4 expression was induced in OIR model for ischemic retinopathy, Angpt4 deficiency did not affect microvascular proliferation, as has been found in *Angpt1^-/-^* ([@bib28]) and *Angpt2^-/-^* mice ([@bib16]), suggesting that Angpt4 is functionally different. On the other hand, in addition to ligand-specific effects, our in vitro characterization also revealed redundant functions between angiopoietins 1 and 4, suggesting that differential, spatiotemporally regulated expression provides an important mechanism for complementary and sequential roles of angiopoietins to establish retinal circulation system. Moreover, based on reported venous-specific effects of inducible Tie2 deletion in retina ([@bib5]) and over-activating TIE2 mutations in venous malformations ([@bib19]), Tie2 signaling appears particularly important to venous development that may contribute to the vessel-type-specific phenotype in *Angpt4*^-/-^ mice.

In Angpt4-deficient mice, we observed defective circumferential growth of peripheral veins postnatally and changes in neuronal cell organization and function in adult mice. Based on Poiseuille\'s equation, vessel flow is proportional to its radius. In line with this suggestion, functional tests using fluorescent tracers showed decreased venous flow in *Angpt4*^-/-^ retinas and we propose that alterations in neural cells are secondary to venous remodeling defect. While ultrastructural changes in neural cell somas closely resembled intracellular edema ([@bib30]), in Müller cells we observed discontinuation of cellular processes in the affected areas but no increase in Müller cell volume in the INL. Changes in Müller cells occur in retinal pathologies involving edema and are associated with altered expression of AQP4 water or Kir4.1 potassium channel, that may result in dysfunction in water homeostasis in these cells ([@bib7]). In *Angpt4*^-/-^ retinas, we found no changes in either AQP4 or Kir4.1, suggesting that water balance in Müller cells may be retained. Other neuronal cells in the INL (including amacrine and bipolar cells) may lack efficient water transport mechanism and thus be more vulnerable for alterations in fluid homeostasis due to diminished venous drainage that can be aggravated by the alterations in Müller cell architecture. We did not find evidence of interstitial edema, either. In literature, there is no similar pathology than what we observe in *Angpt4*^-/-^ mice (congenital decrease in vein diameter, venous SMC abnormality, diminished vein flow, but no inflammation or leakage), making direct comparison to the better characterized retinal pathologies (such as diabetic retinopathy and retinal vein occlusion) difficult. It may be possible that interstitial edema is prominent in retinal vascular diseases in which vascular barrier is disrupted, which causes large increase in fluid entry that is excessive for exit mechanisms.

Overall, our study unraveled unknown physiological functions of poorly characterized Angpt4 in venous development and identified ligand-specific and redundant functions among the family of angiopoietins. Angpt/Tie signaling pathway has emerged as an important target for drug development in ophthalmological diseases ([@bib38]). In addition to providing novel insights into developmental angiogenesis, thorough investigation of all angiopoietin ligands is necessary to fully evaluate the therapeutic potency of this signaling system.

Materials and methods {#s4}
=====================

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\        Designation                                                         Source or\                   Identifiers                                                                   Additional\
  (species)\                                                                               reference                                                                                                  information
  or resource                                                                                                                                                                                         
  -------------------- ------------------------------------------------------------------- ---------------------------- ----------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------
  Strain, strain\      WT                                                                  Charles River Laboratories                                                                                 
  background\                                                                                                                                                                                         
  (*Mus musculus*,\                                                                                                                                                                                   
  C57BL/6N)                                                                                                                                                                                           

  Strain, strain\      *Angpt4*^LacZ^                                                      This Paper                                                                                                 Generation described in detail in Materials and methods
  background\                                                                                                                                                                                         
  (*Mus musculus*,\                                                                                                                                                                                   
  C57BL/6N)                                                                                                                                                                                           

  Strain,\             *Angpt4*^Cre^                                                       This Paper                                                                                                 Generation describedin detail in Materials and methods
  strain background\                                                                                                                                                                                  
  (*Mus musculus*,\                                                                                                                                                                                   
  C57BL/6N)                                                                                                                                                                                           

  Strain,\             *Angpt4*^Cre^; *Rosa26*^mTmG^                                       This Paper                                                                                                 Generation describedin detail in Materials and methods
  strain\                                                                                                                                                                                             
  background\                                                                                                                                                                                         
  (*Mus musculus*,\                                                                                                                                                                                   
  C57BL/6N)                                                                                                                                                                                           

  Strain, strain\      *Egln1*^loxP^                                                       Other                                                                                                      A gift from Prof. Johanna Myllyharju, University of Oulu
  background\                                                                                                                                                                                         
  (*Mus musculus*,\                                                                                                                                                                                   
  C57BL/6N)                                                                                                                                                                                           

  Cell line\           Human umbilical\                                                    Promocell                    C-12203                                                                       
  (human)              vein endothelial cells (HUVEC)                                                                                                                                                 

  Cell line\           TIE2-WT HUVEC                                                       [@bib37]                                                                                                   
  (human)                                                                                                                                                                                             

  Cell line\           TIE2-GFP HUVEC                                                      [@bib37]                                                                                                   
  (human)                                                                                                                                                                                             

  Cell line\           HUVEC vANGPT1                                                       This Paper                                                                                                 Generation described in detail in Materials and methods
  (human)                                                                                                                                                                                             

  Cell line\           HUVEC vANGPT2                                                       This Paper                                                                                                 Generation describedin detail in Materials and methods
  (human)                                                                                                                                                                                             

  Cell line\           HUVEC vANGPT4                                                       This Paper                                                                                                 Generation described\
  (human)                                                                                                                                                                                             in detail in Materials and methods

  Cell line\           Human umbilical artery smooth muscle cells                          Cell Applications            252--05 n                                                                     
  (human)                                                                                                                                                                                             

  Cell line\           Human umbilical vein smooth muscle cells                            Cell Applications            250--05 n                                                                     
  (human)                                                                                                                                                                                             

  Cell line\           Human fibroblasts                                                   ATCC                         CCL-210; RRID:[CVCL_2382](https://scicrunch.org/resolver/CVCL_2382)           
  (human)                                                                                                                                                                                             

  Antibody             αSMA, alpha smooth muscle cell, Cy3-conjugated (Mouse monoclonal)   Sigma-Aldrich                C6198; RRID:[AB_476856](https://scicrunch.org/resolver/AB_476856)             IF (1:300)

  Antibody             IB4, biotinylated isolectin B4                                      Vector laboratories          B-1205; RRID:[AB_2314661](https://scicrunch.org/resolver/AB_2314661)          IF (1:300)

  Antibody             ColIV (rabbit polyclonal)                                           Merck Millipore              AB756P; RRID:[AB_2276457](https://scicrunch.org/resolver/AB_2276457)          IF (1:300)

  Antibody             GFAP (rabbit polyclonal)                                            Abcam                        ab7260; RRID:[AB_305808](https://scicrunch.org/resolver/AB_305808)            IF (1:300)

  Antibody             Pimonidazole (rabbit antisera)                                      Hypoxyprobe                  Pab2627; RRID:[AB_1576904](https://scicrunch.org/resolver/AB_1576904)         IF (1:300)

  Antibody             SM22alpha (goat polyclonal)                                         Abcam                        ab10135; RRID:[AB_2255631](https://scicrunch.org/resolver/AB_2255631)         IF (1:300)

  Antibody             Tie2, clone Ab33 (mouse monoclonal)                                 Merck Millipore              05--584; RRID:[AB_309820](https://scicrunch.org/resolver/AB_309820)           IF (1:100); WB (1:1000)

  Antibody             Tie2 (rabbit polyclonal)                                            Santa Cruz Biotechnology     sc-324; RRID:[AB_631102](https://scicrunch.org/resolver/AB_631102)            WB (1:1000)

  Antibody             pTie2 (Tyr992) (rabbit polyclonal)                                  Cell Signaling               4221S; RRID:[AB_2203198](https://scicrunch.org/resolver/AB_2203198)           IF (1:100); WB (1:1000)

  Antibody             phospho-tyrosine,\                                                  Merck Millipore              05--321; RRID:[AB_309678](https://scicrunch.org/resolver/AB_309678)           WB (1:1000)
                       clone 4G10 (mouse monoclonal)                                                                                                                                                  

  Antibody             penta-HIS\                                                          Qiagen                       34660; RRID:[AB_2619735](https://scicrunch.org/resolver/AB_2619735)           WB (1:1000)\
                       (mouse monoclonal)                                                                                                                                                             

  Antibody             TRITC-phalloidin                                                    Sigma-Aldrich                P1951; RRID:[AB_2315148](https://scicrunch.org/resolver/AB_2315148)           IF (1:2000)

  Antibody             Alexa Fluor 488,\                                                   Jackson ImmunoResearch       016-540-084; RRID:[AB_2337249](https://scicrunch.org/resolver/AB_2337249)     IF (1:300)
                       streptavidin-conjugated                                                                                                                                                        

  Antibody             Alexa Fluor 488, Donkey anti-rabbit                                 Jackson ImmunoResearch       711-545-152; RRID:[AB_2313584](https://scicrunch.org/resolver/AB_2313584)     IF (1:300)

  Antibody             Alexa Fluor 488,\                                                   Jackson ImmunoResearch       715-545-151; RRID:[AB_2341099](https://scicrunch.org/resolver/AB_2341099)     IF (1:300)
                       Donkey anti-mouse                                                                                                                                                              

  Antibody             Alexa Fluor 647,\                                                   Jackson ImmunoResearch       111-605-045; RRID:[AB_2338075](https://scicrunch.org/resolver/AB_2338075)     IF (1:300)
                       Goat anti-rabbit                                                                                                                                                               

  Antibody             Cy3, Donkey anti-goat                                               Jackson ImmunoResearch       705-165-147; RRID:[AB_2307351](https://scicrunch.org/resolver/AB_2307351)     IF (1:300)

  Antibody             Peroxidase-conjugated\                                              Jackson ImmunoResearch       115-035-003; RRID:[AB_10015289](https://scicrunch.org/resolver/AB_10015289)   WB (1:10000)
                       goat anti-mouse                                                                                                                                                                

  Antibody             Peroxidase-conjugated goat anti-rabbit                              Jackson ImmunoResearch       111-035-003; RRID:[AB_2313567](https://scicrunch.org/resolver/AB_2313567)     WB (1:10000)

  Antibody             Anti-Digoxigenin-AP, Fab Fragments                                  Roche                        11093274910; RRID:[AB_514497](https://scicrunch.org/resolver/AB_514497)       ISH (1:1500)

  Antibody             Protein A/G PLUS-Agarose                                            Santa Cruz biotechnology     sc-2003; RRID:[AB_10201400](https://scicrunch.org/resolver/AB_10201400)       

  Sequence-\           qPCR primers                                                        Sigma-Aldrich                                                                                              [Supplementary file 1](#supp1){ref-type="supplementary-material"}
  based reagent                                                                                                                                                                                       

  Sequence-\           mouse *Angpt1* in situ RNA Antisense probe                          This Paper                                                                                                 [Supplementary file 2](#supp2){ref-type="supplementary-material"}; Generation described in detail in Materials and methods
  based reagent                                                                                                                                                                                       

  Sequence-\           mouse *Angpt2* in situ\                                             This Paper                                                                                                 [Supplementary file 2](#supp2){ref-type="supplementary-material"}; Generation described in detail in Materials and methods
  based reagent        RNA Antisense probe                                                                                                                                                            

  Sequence-\           mouse *Angpt4* in situ RNA Antisense probe                          This Paper                                                                                                 [Supplementary file 2](#supp2){ref-type="supplementary-material"}; Generation described in detail in Materials and methods
  based reagent                                                                                                                                                                                       

  Sequence-\           mouse *Tie2* in situ\                                               This Paper                                                                                                 [Supplementary file 2](#supp2){ref-type="supplementary-material"}; Generation described in detail in Materials and methods
  based reagent        RNA Antisense probe                                                                                                                                                            

  Sequence-\           mouse *Angpt1* in situ RNA Sense probe                              This Paper                                                                                                 [Supplementary file 2](#supp2){ref-type="supplementary-material"}; Generation described in detail in Materials and methods
  based reagent                                                                                                                                                                                       

  Sequence-\           mouse *Angpt2* in situ RNA Sense probe                              This Paper                                                                                                 [Supplementary file 2](#supp2){ref-type="supplementary-material"}; Generation described in detail in Materials and methods
  based reagent                                                                                                                                                                                       

  Sequence-\           mouse *Angpt4* in situ\                                             This Paper                                                                                                 [Supplementary file 2](#supp2){ref-type="supplementary-material"}; Generation described in detail in Materials and methods
  based reagent        RNA Sense probe                                                                                                                                                                

  Sequence-\           mouse *Tie2* in situ RNA Sense probe                                This Paper                                                                                                 [Supplementary file 2](#supp2){ref-type="supplementary-material"}; Generation described in detail in Materials and methods
  based reagent                                                                                                                                                                                       

  Sequence-\           Tie2-412 shRNA                                                      The RNAi consortium                                                                                        <http://www.broadinstitute.org/rnai/trc>
  based reagent                                                                                                                                                                                       

  Sequence-\           Tie2-413 shRNA                                                      The RNAi consortium                                                                                        <http://www.broadinstitute.org/rnai/trc>
  based reagent                                                                                                                                                                                       

  Sequence-\           PLKO.1 shRNA                                                        The RNAi consortium                                                                                        <http://www.broadinstitute.org/rnai/trc>
  based reagent                                                                                                                                                                                       

  Peptide,\            ANGPT1                                                              R & D Systems                923-AN-025                                                                    
  recombinant\                                                                                                                                                                                        
  protein                                                                                                                                                                                             

  Peptide,\            COMP-ANGPT1                                                         Other                                                                                                      A gift from Prof. Gou Young Koh, KAIST
  recombinant\                                                                                                                                                                                        
  protein                                                                                                                                                                                             

  Peptide,\            ANGPT2                                                              R & D Systems                623-AN-025                                                                    
  recombinant\                                                                                                                                                                                        
  protein                                                                                                                                                                                             

  Peptide,\            Angpt4                                                              R & D Systems                738-AN-025                                                                    
  recombinant\                                                                                                                                                                                        
  protein                                                                                                                                                                                             

  Peptide,\            ANGPT4                                                              R & D Systems                964-AN-025                                                                    
  recombinant\                                                                                                                                                                                        
  protein                                                                                                                                                                                             

  Commercial\          Mouse Angiopoietin-3 DuoSet ELISA                                   R & D Systems                DY738                                                                         
  assay or kit                                                                                                                                                                                        

  Commercial\          RNeasy Mini Kit                                                     Qiagen                       74104                                                                         
  assay or kit                                                                                                                                                                                        

  Commercial\          Fibrous Tissue Mini Kit                                             Qiagen                       74704                                                                         
  assay or kit                                                                                                                                                                                        

  Commercial\          Caspase-Glo 3/7 Assay                                               Promega                      G8091                                                                         
  assay or kit                                                                                                                                                                                        

  Commercial\          Cell proliferation ELISA, BrdU                                      Roche                        11647229001                                                                   
  assay or kit                                                                                                                                                                                        

  Chemical\            pimonidazole                                                        Hypoxyprobe                  HP3-100Kit                                                                    
  compound, drug                                                                                                                                                                                      

  Chemical\            Evans blue                                                          Sigma-Aldrich                E2129                                                                         
  compound, drug                                                                                                                                                                                      

  Chemical\            Carboxylate-modified fluorescent beads                              Invitrogen                   F888                                                                          
  compound, drug                                                                                                                                                                                      

  Chemical\            5% fluorescein sodium salt                                          Sigma-Aldrich                F6377                                                                         
  compound, drug                                                                                                                                                                                      

  Chemical\            Aprotinin                                                           Sigma-Aldrich                A3428                                                                         
  compound, drug                                                                                                                                                                                      

  Chemical\            BYL719                                                              LC Laboratories              A-4477                                                                        
  compound, drug                                                                                                                                                                                      

  Chemical\            LY294002                                                            Selleck                      S1105                                                                         
  compound, drug                                                                                                                                                                                      

  Chemical\            Protease inhibitor                                                  Sigma-Aldrich                P8340                                                                         
  compound, drug                                                                                                                                                                                      

  Chemical\            Phosphatase inhibitor                                               Sigma-Aldrich                P5726                                                                         
  compound, drug                                                                                                                                                                                      

  Chemical\            Tie2-Fc                                                             R & D Systems                313-TI                                                                        
  compound, drug                                                                                                                                                                                      

  Chemical\            NBT/BCIP stock solution                                             Roche                        11681451001                                                                   
  compound, drug                                                                                                                                                                                      

  Software,\           Olympus Fluoview Ver.3.0 Viewer                                     Olympus                      RRID:[SCR_014215](https://scicrunch.org/resolver/SCR_014215)                  
  algorithm                                                                                                                                                                                           

  Software,\           ZEN 2012 (blue edition)                                             Carl Zeiss                   RRID:[SCR_013672](https://scicrunch.org/resolver/SCR_013672)                  
  algorithm                                                                                                                                                                                           

  Software,\           Fiji (ImageJ)                                                       Fiji                         RRID:[SCR_002285](https://scicrunch.org/resolver/SCR_002285)                  
  algorithm                                                                                                                                                                                           

  Software,\           Biacore T200\                                                       Biacore                                                                                                    
  algorithm            Evaluation Software,\                                                                                                                                                          
                       version 2.0                                                                                                                                                                    

  Software,\           OriginPro 2018b                                                     OriginLab\                   RRID:[SCR_014212](https://scicrunch.org/resolver/SCR_014212)                  
  algorithm                                                                                Corporation                                                                                                

  Software,\           Microsoft Excel 2016                                                Microsoft\                   RRID:[SCR_016137](https://scicrunch.org/resolver/SCR_016137)                  
  algorithm                                                                                Office                                                                                                     

  Other                DAPI                                                                Sigma-\                      D9542                                                                         IF (1:500)
                                                                                           Aldrich                                                                                                    
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Statistics {#s4-1}
----------

Kruskal--Wallis and Mann--Whitney *U* tests were used in [Figure 8A](#fig8){ref-type="fig"}. Otherwise, comparisons between two groups were done using two-tailed Student's t-test and multiple comparison with ANOVA followed by the Bonferroni post-hoc test.

Study approval {#s4-2}
--------------

Experiments involving mice were performed under permissions from the National Animal Experiment Board following the regulations of the EU and national legislation.

Generation, maintenance and genotyping of the transgenic mouse lines {#s4-3}
--------------------------------------------------------------------

For *Angpt4*^LacZ^ mouse model, clone HTGRS06013 A 1 C06 was obtained from the trans-NIH Knock-Out Mouse Project (KOMP) and the KOMP Repository ([www.komp.org](http://www.komp.org)). The AsiSI-linearized targeting construct was electroporated into B6 ES cells and selected with G418. Genomic DNA isolated from resistant colonies was screened by PCR. The PCR assay for the targeted *Angpt4* gene used the primer pair 5′-cacaacgggttcttctgttagtcc-3′ from construct and 5′-gcgaaggagcggctgagcctgagaactc-3′ from *Angpt4* gene. Correctly targeted clones were injected into C57BL/6N blastocysts, and two separate mouse lines were generated by standard methods.

Targeting vector for *Angpt4*^Cre^ mouse line was generated by using recombineering approach as described previously ([@bib47]). Briefly, BAC-clones RP23-204D14 and RP23-131K21 overlapping genomic *Angpt4* locus were obtained from BACPAC resources (Children\'s Hospital Oakland). Bacterial cells carrying BAC-clones were electroporated with pSC101-Bad-gbaA vector. A Cre-Neo-cassette with homologous arms flanking the first exon (5′-ggctgtgaggagttacctgtcctggtacctgacaagaccacctcaccaccacttggtctc-Cre-pA-Frt-Neo-pA-Frt-tacagctggggtcgtgtgatgggctagagggtggctaggggactgcccgatcaccaggt-3′) was electroporated into the cells to replace the first exon. Next, a targeting vector was cloned into the p15A-amp-HSV-DTA-rpsL-BSD plasmid. First two homologous arms were generated by PCR and ligated into P15A-amp-HSV-DTA-rpsL-BSD plasmid; used primers for generating homologous arms were 5′-atacggccgattggtatcaagaagcatgttagc-3′, 5′-ggtttcaaacag[actagt]{.ul}tgcttcagggtataggcagcccag-3′ and 5′-taccctgaagca[actagt]{.ul}ctgtttgaaacctgtgcagatatg-3′, 5′-tatgtcgacaccactggatgagggatgaggcaac-3′. Then the vector was linearized by SpeI restriction enzyme (underlined in primers) and electroporated into bacterial cells having BAC-clones with CRE-cassette in *Angpt4* locus. Colonies were picked and confirmed by sequencing. The resulting targeting vector contained 1.2 and 11.4 kb genomic arms and Cre-pA-Frt-Neo-pA-Frt cassette inserted into the first exon of the *Angpt4* gene. The AflI linearized targeting construct was electroporated into B6 ES cells and selected with G418. Genomic DNA isolated from resistant colonies was screened by PCR. The PCR assay for the targeted *Angpt4* gene used the primer pair 5′-atcactcgttgcatcgaccggtaatgc-3′ from Cre-cassette and 5′-ctgggccaggtttggttttctctg-3′ from *Angpt4* promotor region. Correctly targeted clones were injected into C57BL blastocysts, and two separate mouse lines were generated by standard methods. An Frt-flanked Neo cassette (for selection of correctly targeted ES cells) was removed from *Angpt4*^frt-Neo-frt-Cre^ mouse line by crossing with the ACTB-FLPe transgenic mouse line. Deletion of Neo-cassette in *Angpt4*^Cre^ was confirmed by PCR.

The ACTB-FLPe ([@bib36]) and mT/mG ([@bib31]) mice were maintained and genotyped as reported. The *Egln1*^loxP^ mouse line was a generous gift from Professor Johanna Myllyharju (University of Oulu). The transgenic mice were maintained in the C57Bl/6N background and littermates were used as controls.

Mice were usually analyzed at four different time points that reflected early (around P4) venous development and maturation phase (around P12). Two months old mice were considered as adults (fully maturated) and aged mice (8--11 months) were used to investigate progression of retinal pathologies.

Angiopoietin gene nomenclature {#s4-4}
------------------------------

Nomenclature is based on gene naming guidelines of the HUGO Gene Nomenclature Committee (HGNC, [www.genenames.org](http://www.genenames.org)) and the Mouse Genome Informatics (MGI, [www.informatics.jax.org](http://www.informatics.jax.org)).

Retina preparation, whole mount staining and imaging {#s4-5}
----------------------------------------------------

*Angpt4*^Cre^; *Rosa26* ^mT/mG^ mice eyes were fixed in 4% PFA, retinas were dissected and flattened in Immu-Mount (Thermo Scientific) between cover and objective glass for microscopy analysis. For retina immunofluorescent staining, dissected retinas were treated for 1 hr with cold methanol, permeabilized and blocked for 2 hr with 50% BSA--1% Triton--1xPBS. Primary antibody stainings were carried out overnight using Cy3-αSMA (C6198, Sigma-Aldrich), SM22 alpha (ab10135, Abcam), ColIV (AB756P, Merck Millipore), GFAP (ab7260, Abcam), pimonidazole (Pab2627, Hypoxyprobe) and biotinylated isolectin B4 (B-1205, Vector) antibodies, and visualized with Alexa Fluor 488 streptavidin, Alexa Fluor 488-, Alexa Fluor 647- and Cy3-conjugated secondary antibodies (Jackson ImmunoResearch). Retinas were imaged using Olympus FluoView FV1000 or Zeiss LSM780 confocal microscope. Coverage of αSMA-positive cells was quantified from branching point region of two largest veins at peripheral area of retina. The width of the veins was measured just below the venal branching point at peripheral retina or close to optic nerve head for comparison. 5-Bromo-4-chloro-3-indolyl β-D-galactosidase (X-Gal) staining of retinas was performed as described in [@bib14].

Quantitative RT-PCR {#s4-6}
-------------------

Total RNA was extracted by using RNeasy Mini or Fibrous Tissue Mini Kit (Qiagen) following manufacturer´s protocol. For cDNA synthesis, 1 or 3 μg of RNA was mixed with random hexamers and oligo-dT, 200 U M-MLV Reverse Transcriptase (Promega), 20 U RiboLock RNase inhibitor (Thermo Scientific), 0.5 mmol/L dNTP and reaction buffer (50 mmol/L Tris-HCl, 75 mmol/L KCl, 3 mmol/L MgCl~2~), incubated at +42°C for 1 hr, then at +70°C for 15 min and diluted 1:3 or 1:10 in sterile H~2~O to be used in qPCR (2 μl/reaction). Real-time qPCR was performed using Stratagene mx3005P (Agilent Technologies) or CFX96 (Bio-Rad) qPCR instruments and Brilliant Ultra-Fast SYBR QPCR Master mix (Agilent Technologies). DNA primer sequences are indicated in the [Supplementary file 1](#supp1){ref-type="supplementary-material"}.

Low oxygen treatment {#s4-7}
--------------------

Four weeks old *Angpt4*^Cre^; *Rosa26* ^mT/mG^ mice were exposed to low oxygen (12% O~2~) for 8 days in a hypoxic chamber (COY Lab Products). Mice from the same litters were exposed to normoxia (21% O~2~) as a control. Eyes were fixed in 4% PFA fixative and retinas were dissected and flat-mounted for microscopy. The relative intensity of GFP indicating the Angpt4-positive astrocytes was analyzed by ImageJ software tool.

Oxygen-induced retinopathy (OIR) model {#s4-8}
--------------------------------------

The OIR model was generated by exposing P7 mice to 75% oxygen in a hyperoxic chamber (controlled by ProOx Model 110, BioSpherix) for 5 days with their nursing females and then returning them to room air for 5 days. Retinas were harvested at P17.

Hyperoxia model {#s4-9}
---------------

Litters of P7 C57BL/6N and *Angpt4*^Cre^; *Rosa26*^mTmG^ pups along with their nursing females were placed in a 75% oxygen atmosphere in a chamber (controlled by ProOx Model 110, BioSpherix) for 5 days. P12 mice were sacrificed and the eyes were enucleated. Control pups were raised under normoxic conditions and sacrificed at P12.

Pimonidazole hypoxia staining {#s4-10}
-----------------------------

Vascular infusions were performed under isoflurane (1.5--2.5%) anesthesia. Before operation analgesics Karprofen (5 mg/kg) and Bubrenorfin (0.1 mg/g) were administered s.c. Pimonidazole (50 μg/μl) in 0.9% NaCl with or without 2% Evans blue was administered via femoral vein 60 mg/kg. After 1 hr, mice were sacrificed by cervical dislocation. The eyes were collected and fixed in 4% PFA for 1.5 hr at room temperature, followed by retina preparation, whole mount staining and imaging.

Fluorosphere clearance from peripheral annular vein {#s4-11}
---------------------------------------------------

Carboxylate-modified fluorescent beads (Invitrogen; 0.5 μm in diameter, excitation and emission maximum, 505/515 nm; stock concentration 2% by weigh) were diluted in 0.9% NaCl containing 3‰ Evans blue (Sigma-Aldrich) and sonicated. The left external carotid artery was permanently ligated to insert \<200 µm polyethylene cannula via small arteriotomy. The cannula filled with 1% heparin was secured with silk suture the tip residing at the site from which external carotid artery is branched. 100 µl of fluorescent beads were administered with 500 µl/min flow rate directly into common carotid artery, where it is conducted into internal carotid artery that supplies the blood to the ophthalmic artery. Mice were euthanized 27 s after the administration of fluorospheres by cervical dislocation, eyes were collected, and the distribution of fluorospheres was evaluated by confocal microcopy in whole mount preparations. For quantification, number of individual spheres was counted from images, and results were normalized by the length of venous segment analyzed.

In vivo imaging {#s4-12}
---------------

The animals were anesthetized by mixture of ketamine (5 mg/kg) (Ketaminol, Intervet International) and medetomidine (0.04 mg/kg) (Domitor, Orion). Both pupils were dilated with topical tropicamide (Oftan tropicamid, 5 mg/ml, Santen). To prevent corneal desiccation during procedure, topical Systane Ultra lubricant eye drop (Alcon) was applied.

Fluorescein angiography (FA) {#s4-13}
----------------------------

The mice received intraperitoneal injections of 100 μl of 5% fluorescein sodium salt (Sigma-Aldrich). Imaging was done using Heidelberg Spectralis HRA2 system (Heidelberg Engineering). Starting before the administration of sodium fluorescein a video was recorded showing the expansion of fluorescein through the retinal vascular system. In addition, snapshot images were taken every 30 s from the retinal focus level for a period of 5 min after sodium fluorescein injection. To interpret venous filling from fluorescein angiograms, fluorescein intensities were measured (ImageJ) from a video frame representing an early filling phase (arterial signal visible, but not saturated, less than 30 s from fluorescein administration). Venous intensities were normalized by an average arterial intensity from the same eye. Possible leakage was evaluated after complete filling of the retinal arteries, capillaries and veins 5 min after fluorescein administration.

Flash electroretinography measurements (fERG) {#s4-14}
---------------------------------------------

Animals were dark-adapted for 12 hr prior to the ERG and all the ERG recordings were performed under dim red light. Mice were anesthetized as described for the in vivo imaging. The body temperature was maintained by using a physiological heating pad set to 38°C. Eyes were locally anesthetized by topical application of a single drop of oxybuprocaine (Oftan Obucain 4 mg/ml, Santen). Thereafter, eyes were fully dilated by applying drops of atropine (Oftan tropicamid 5 mg/ml, Santen) and phenylephrine hydrochloride (Oftan metaoksedrin 100 mg/ml, Santen). During the recording, eyes were kept moist with a drop of physiological saline. The a- and b-wave amplitude and latency were analysed at 0.003, 0.01, 0.1, 1, 3, and 10 cd.s/m^2^.

Histology and immunohistochemistry {#s4-15}
----------------------------------

Mice were sacrificed by CO~2~ asphyxiation. Tissues were collected, frozen in OCT medium (Tissue Tek) and sectioned or fixed in neutral formalin and processed for paraffin sectioning. Sections of 5 μm were stained with standard Masson's trichrome, PAS or IHC methods. 

In situ hybridization {#s4-16}
---------------------

Enucleated eyes from C57BL/6N (WT) or *Angpt4^-/-^* mice were fixed in 4% PFA for 30 min, retinas were dissected and stored in methanol at −20°C. Upon hybridization, retinas were fixed in 4% PFA for 5 min, washed with Depc-treated PBS--0.1% Tween 20 (PBT), digested with 250 µg/ml proteinase K--0.2% SDS in PBT for 5 min and postfixed in 4% PFA--0.2% glutaraldehyde for 4 min. After brief washes with Depc-PBT and hybridization buffer (50% formamide, 5xSSC pH 4.5, 1% SDS, 50 µg/ml tRNA, 50 µg/ml heparin), retinas were hybridized with 1 µg/ml digoxigenin (DIG)-labelled mouse *Tie2*, *Angpt1*, *Angpt2* or *Angpt4* antisense or sense cRNA probes in hybridization buffer overnight at 65°C. Probe synthesis was performed as described previously ([@bib35]). Briefly, pBluescript II SK(+) plasmids containing 1 kb *Tie2* or 0.5 kb *Angpt1*, *Angpt2* or *Angpt4* cDNA (primers used for cloning are indicated in [Supplementary file 2](#supp2){ref-type="supplementary-material"}) were linearized with HindIII for antisense and BamHI for sense RNA probes, and DIG-labelled RNA probes were transcribed using T3 or T7 polymerases (Promega), respectively, and DIG-RNA labeling mix (Roche). After hybridization, retinas were first washed with 50% formamide--1xSSC for 1 hr at 65°C, then with 100 mM maleic acid buffer containing 0.1% Tween 20 (MABT) for 40 min and blocked with 2% nucleic acid blocking reagent (Roche)--10% sheep serum in MABT for 30 min at room temperature. Retinas were incubated with anti-DIG-AP antibody (Roche) in 2% blocking reagent--1% sheep serum overnight at 4°C. After washes with MABT, retinas were briefly equilibrated in NTMT buffer (100 mM Tris pH 9.5, 100 mM NaCl, 5 mM MgCl~2~, 0.1% Tween 20) and color was developed with 20 µl/ml NBT/BCIP stock solution (Roche) in NTMT--5% polyvinyl alcohol at room temperature. When staining intensity was sufficient (after 6--8 hr), retinas were thoroughly washed with PBT and fixed in 4% PFA for 1 hr at room temperature. When indicated, immunofluorescent staining was carried out as described before ([@bib35]) by using GFAP primary antibody (ab7260, Abcam). Finally, retinas were flat-mounted and imaged with Zeiss Axio Imager motorized bright field microscope or Zeiss LSM780 confocal microscope. Overlay of confocal and bright field images was generated by ZEN (blue edition) software (Carl Zeiss). Atriums were processed otherwise similarly but they were stored in PBS and imaged with a stereomicroscope.

Transmission electron microscopy (TEM) {#s4-17}
--------------------------------------

Eyes were fixed in 1% glutaraldehyde and 4% formaldehyde in 0.1 mol/l phosphate buffer, pH 7.4, then postfixed in 1% osmium tetroxide, dehydrated in acetone and embedded in Epon LX112 (Ladd Research Industries). 1 μm sections were stained with toluidine blue to select regions of interest. 80 nm sections were cut with a Leica Ultracut UCT microtome and imaged using Tecnai Spirit transmission electron microscope (Fei Europe) and Quemesa CCD camera (Olympus Soft Imaging Solutions GMBH). Cellular location of β-galactosidase enzyme activity (electron dense crystals) was imaged as previously described ([@bib26]).

Angpt4 ELISA {#s4-18}
------------

Whole blood was collected from P12 mice by heart puncture immediately after sacrificing. Serum was separated by centrifugation for 10 min at 400 g at room temperature. To isolate retinal soluble extracellular and vitreous proteins, 1--2 eyes were cut open in Reagent Diluent (1% BSA in PBS, pH 7.2--7.4), sclera and lens were removed, and cellular fraction of retinas was pelleted for 5 min at 2400 g and supernatant was collected. Angpt4 level was quantified by Mouse angiopoietin-3 DuoSet ELISA kit (D4738, R & D Systems) by following the manufacturer's protocol. Absorbance at 450 nm was measured with VICTOR^3^V 1420 Multilabel Counter (Perkin Elmer).

Cell culture {#s4-19}
------------

HUVECs (PromoCell) were cultured in M200 basal medium (Medium 200 with low-serum growth supplement, Cascade Biologics), supplemented with penicillin-streptomycin (Sigma-Aldrich) and 10% FBS (HyClone). The cell culture plates for HUVECs were coated with Attachment Factor (Cell Applications) at least for 30 min at 37°C in 5% CO~2~ before seeding the cells. HUVECs transduced with full length wild type (WT) human TIE2 (TIE2-WT HUVEC), TIE2-GFP, ANGPT1, ANGPT2, or ANGPT4 were generated via retroviral gene transfer as previously described ([@bib37]). Human umbilical artery (aSMC, Cell Applications) and human umbilical vein (vSMC, Cell Applications) smooth muscle cells were cultured in Smooth Muscle Cell Growth Medium (SMCGM, Cell Applications) according to the manufacturer's protocol. Human fibroblast cell line CCL-210 (ATCC) was cultured in DMEM (Gibco) supplemented with 10% FBS. All cell lines were tested mycoplasma negative when received from the manufacturer and regularly while performing the experiments.

Astrocyte isolation and culture {#s4-20}
-------------------------------

Astrocytes were isolated from P3 mice brains. The brains were washed in HBSS. The cortex of the brain was dissected: Hemispheres were removed from the diencephalons and brain stem. Each hemisphere was laid on the lateral side with internal side facing up. The meninges were grasped around the olfactory bulb and pulled away gently. The dissected cortex was digested for 2 min in trypsin-EDTA (Invitrogen) and washed with HBSS. Cortexes were gently pipetted to single cell suspension and plated on poly-D-Lysin (Sigma)-coated cell culture plates. Astrocytes were grown in DMEM containing 1 g/l glucose and no L-Glutamin (Gibco), supplemented with penicillin-streptomycin (Sigma-Aldrich) and 20% FBS (HyClone). The FBS concentration was changed to 10% 48 hr after seeding. Primary cultures were stained for GFAP (ab7260, Abcam) to confirm their astrocyte identity.

Recombinant angiopoietins {#s4-21}
-------------------------

Purified recombinant human ANGPT1, ANGPT2, and ANGPT4 and mouse Angpt4 were from R & D Systems. COMP-ANGPT1 was a kind gift from Gou Young Koh.

Fibrin gel assay {#s4-22}
----------------

HUVECs were transduced with ANGPT1, ANGPT2 or ANGPT4 cDNAs or shRNA constructs TIE2-412, TIE2-413 or PLKO.1 control (acquired from RNAi consortium shRNA library, <http://www.broadinstitute.org/rnai/trc>) or left untransduced as a control. Alternatively, spheroids were stimulated with purified recombinant angiopoietins (below). Cells were suspended in SMCGM or M200 medium supplemented with 10% FBS, 1% penicillin/streptomycin, LSGS supplement and 0.32% methylcellulose, pipetted as drops to cell culture plates and incubated as hanging-drops overnight at 37°C in 5% CO~2~ to form EC-spheroids of 750 cells and in co-culture spheroids 750 cells for each cell line. The next day, spheroids were washed with 10% FBS in 1xPBS, collected into tubes of approximately 15 spheroids and suspended in 250 µl of supplemented M200 or SMCGM medium containing 3.2 mg/ml fibrinogen and 0.32% methylcellulose and pipetted into a 48-well with 0.5 U thrombin in the bottom. After 2 hr of polymerization at 37°C in 5% CO~2~, 300 µl of medium was added on top of the gels. Where mentioned, both the gels and the media were supplemented with 26 µg/ml serine protease inhibitor aprotinin (Sigma-Aldrich), 5 µM BYL719 (also known as alpelisib, a selective inhibitor for PI3-kinase catalytic subunit p110α, LC Laboratories) or 10 µM PI3K inhibitor LY294002 (Selleck) and/or 500 ng/ml of purified human recombinant ANGPT1, ANGPT2 or ANGPT4 or purified mouse recombinant Angpt4 (R & D Systems). After 24 hr, the cells were fixed with 4% PFA overnight at 4°C, stained with DAPI as described before ([@bib25]) and imaged with Olympus FluoView FV1000 confocal microscope. Spheroid and lumen areas from digitized images were quantified by Olympus Fluoview Ver.3.0 Viewer. Non-stimulated HUVEC control spheroid lumen sizes were normalized to their average lumen size in independent experiments. Lumen sizes in stimulated or inhibited spheroids were normalized to non-stimulated HUVEC control lumen size within each individual experiment.

Quantification of TIE2 activation in cell--cell junctions {#s4-23}
---------------------------------------------------------

TIE2-WT HUVECs were seeded on coverslips in a 24-well plate overnight. The cells were stimulated with angiopoietins (500 ng/ml) in M200 basal medium for 1 hr at 37°C in 5% CO~2~. Cells were fixed in 4% PFA for 15 min, permeabilized in 0.5% TritonX-100 in PBS for 3 min and stained for anti-TIE2 (total TIE2, Ab33, Merck Millipore) and anti-phosphorylated TIE2 (pTIE2, Y992, Cell Signaling) antibodies. The cells were imaged with LSM780 confocal microscope (Carl Zeiss) with a Plan-Apochromat 40x/1.4 objective, and ratio of pTIE2/total TIE2 staining intensity at cell--cell junctions was quantified by using ZEN 2012 (blue edition) software (Carl Zeiss).

Cell lysis, immunoprecipitation and western blotting {#s4-24}
----------------------------------------------------

Cells were lysed in cell lysis buffer (9.1 mM Na2HPO4, 1.7 mM NaH2PO4, 1% NP-40, 0.25% sodium deoxycholate, 150 mM NaCl, 0.1% SDS, 1 mM EDTA) containing protease and phosphatase inhibitors (P8340 and P5726, Sigma-Aldrich). For immunoprecipitation, cell lysate was incubated with TIE2 antibody (sc-324, Santa Cruz Biotechnology) for 1 hr at +4°C in rotation, after which Protein A/G PLUS-Agarose (sc-2003, Santa Cruz biotechnology) was added and incubation continued overnight at +4°C in rotation, followed by washing three times with RIPA buffer. For western blot analysis, proteins were either left non-reduced or reduced by boiling for 5 min with 1% 2-mercaptoethanol (Sigma-Aldrich). Proteins were separated with SDS-PAGE and transferred into nitrocellulose membrane, followed by blocking in 5% milk powder in 0.05% Tween-PBS for 1 hr and incubation with penta-HIS (34660, Qiagen), phosphotyrosine (4G10, Merck Millipore) or TIE2 (Ab33, Merck Millipore) antibody dilutions overnight at +4°C. Primary antibodies were detected by horseradish peroxidase conjugated secondary antibodies (Jackson ImmunoResearch) with Lumi-light western blotting substrate (Roche) and signals were imaged by LAS 3000 luminescent image analyzer (Fujifilm).

Angiopoietin binding to endothelial cell (EC) extracellular matrix (ECM) {#s4-25}
------------------------------------------------------------------------

The EC ECM fraction was generated by culturing HUVECs until confluency on coverslips, after which the cellular fraction was dissolved with 0.1% Tween-20 in PBS overnight at 4°C on a vertical shaker, and then suspended and washed vigorously until the cells were detached. His-tagged angiopoietins (500 ng/ml) in M200 basal medium were allowed to bound to the HUVEC ECM for 1 hr at 37°C in 5% CO~2~. Penta-His (34660, Qiagen) and HRP-conjugated secondary antibodies (Qiagen) were used to detect ECM bound angiopoietins. Washes between steps were performed with 1xPBS (with Ca and Mg), 0.05% Tween-20, pH 7.4. TMB X-tra substrate (Kem-En-Tec Diagnostics) was added for 13 min, the reaction was stopped with 0.2 M H~2~SO~4~, and the absorbance was measured at 450 nm with VICTOR^3^V 1420 Multilabel Counter (Perkin Elmer). Anti-TIE2 antibody (Merck Millipore) was used as a control for successful removal of TIE2 positive cell membrane, and anti-FN antibody (Santa Cruz Biotechnology) as a positive control for the presence of ECM in the preparations.

Cell spreading assay on substrate-linked angiopoietins {#s4-26}
------------------------------------------------------

Coverslips were first coated with penta-His antibody (2.1 µg/ml) (34660, Qiagen) overnight at 4°C, followed by blocking with 1% heat-inactivated BSA-PBS for 2 hr at room temperature. Recombinant His-tagged angiopoietins (500 ng/ml in blocking buffer) were bound overnight at 4°C. For negative controls, coverslips were only coated with penta-HIS antibody (34660, Qiagen). For positive controls, coverslips were coated with fibronectin (FN, 20 µg/ml, R & D systems). 20,000 TIE2 WT-HUVECs per coverslip were allowed to spread for 1 hr in M200 basal medium at 37°C in 5% CO~2~. The cells were then fixed and stained with TRITC-phalloidin (P1951, Sigma-Aldrich). The cells were imaged with LSM780 confocal microscope with a Plan-Apochromat 40x/1.4 objective, and cell area was measured with ImageJ software.

Angiopoietin--TIE2 binding affinity analysis by ELISA {#s4-27}
-----------------------------------------------------

96-well plates (MaxiSorp Surface, Nunc International) were coated with 4, 250 or 500 ng/ml purified human and mouse recombinant angiopoietins in PBS overnight at 4°C, followed by blocking with 1% heat-inactivated BSA-PBS (with Ca and Mg) for 1 hr. The human TIE2-Fc (250 ng/ml, R & D Systems) receptor ligand binding domain in blocking buffer was let to bind to the ligands for 15 min. Anti-human IgG Fc-tail antibody with conjugated HRP (Jackson ImmunoResearch) was used for 1 hr, TMB X-tra substrate (Kem-En-Tek Diagnostics) was added for 13 min, and the reaction was stopped with 0.2 M H~2~SO~4~. The absorbance was measured at 450 nm with VICTOR^3^V 1420 Multilabel Counter (Perkin Elmer).

TIE2-GFP fluorescence recovery after photobleaching (FRAP) {#s4-28}
----------------------------------------------------------

The FRAP experiments were performed using TIE2-GFP HUVECs on glass bottomed cell culture dishes in the presence or absence of human or mouse recombinant purified angiopoietins (500 ng/ml) in environmentally controlled microscopy stage incubator. Regions of interest (ROIs) were defined and photobleached at retracting cell edges at the cell--ECM interface using the maximum laser power (405 nm) with 16 iterations. Fluorescence recovery was followed every 5 s for a period of 5 to 10 min. The following equation was used to determine the normalized fluorescence intensity (NFI):$$NFI = \frac{ROI\left( t \right) - BG\left( t \right)}{Tot\left( t \right) - BG\left( t \right)}x\frac{Tot\left( t_{0} \right) - BG\left( t_{0} \right)}{ROI\left( t_{0} \right) - BG\left( t_{0} \right)}$$where *BG* stands for background, *Tot* for non-bleached control ROI, and *t* for time. The plateau point was determined as a postbleach point, after which the fluorescence signal stayed constant. The mobile fraction (Mf) was determined by:$$f = \frac{{NFI}_{0} + NFI}{{NFI}_{0}}$$where NFI~0~ stands for the NFI in the prebleach period. Images were captured by a Zeiss LSM780 confocal microscope system with a Plan-Apochromat 40x/1.4 objective, and the time-lapse data was analyzed by ZEN 2012 (blue edition) software (Carl Zeiss).

Detection of angiopoietin--TIE2 binding by surface plasmon resonance {#s4-29}
--------------------------------------------------------------------

Binding kinetics of angiopoietins to TIE2 were measured by using a Biacore T200 instrument (GE Healthcare). Purified human TIE2-Fc (R & D Systems) was immobilized to a CM5 sensor chip (5313 RU) by using standard amine coupling in 10 mM acetate buffer, pH 4. An additional channel without coating was used in parallel as a blank channel. All samples were injected sequentially onto the sTIE2 surface at 0--200 nM concentrations in PBS using a flow rate of 30 µl/min. The 2.5 nM concentration was run in duplicate. Association time was 120 s and dissociation time 600 s. The alterations in the refractory index were recorded as relative response unit (RU).

Cell proliferation assay {#s4-30}
------------------------

10,000 aSMC or vSMC cells per 96-well were seeded. SMCs were stimulated with angiopoietins (500 ng/ml) in SMCGM for 24--48 hr at 37°C in 5% CO~2~. Cell proliferation was detected by Cell Proliferation ELISA BrdU kit (11647229001, Roche) following the manufacturer's protocol. Absorbance at 450 nm was measured with VICTOR^3^V 1420 Multilabel Counter (Perkin Elmer).

Caspase-Glo 3/7 apoptosis assay {#s4-31}
-------------------------------

10,000 aSMC or vSMC cells per 96-well were seeded. SMCs were stimulated with angiopoietins (500 ng/ml) in DMEM without serum or supplements for 24--72 hr at 37°C in 5% CO~2.~ Cell apoptosis was detected by Caspase-Glo 3/7 Assay kit (G8091 Promega) following the manufacturer's protocol. Luminescence was measured with VICTOR^3^V 1420 Multilabel Counter (Perkin Elmer).

Cell migration assay {#s4-32}
--------------------

aSMC or vSMC cells were grown to full confluency in SMCGM media. A wound was scratched in each well with a 120 µl tip, after which the detached floating cells were washed away with DMEM. The wound closure was followed every 15 min for 48--96 hr in the presence of angiopoietin (500 ng/ml) stimulus in DMEM with Olympus IX81 microscope equipped with motorized stage incubator and CPlanFLN PhC 10x/0.30 objective. Images were captured with Olympus XM10 CCD camera and wound closure was analyzed by ImageJ software.

Funding Information
===================

This paper was supported by the following grants:

-   http://dx.doi.org/10.13039/501100002341Academy of Finland 251314 to Lauri Eklund.

-   http://dx.doi.org/10.13039/501100002341Academy of Finland 136880 to Lauri Eklund.

-   http://dx.doi.org/10.13039/501100002341Academy of Finland 310986 to Lauri Eklund.

We thank Jaana Träskelin, Riitta Jokela and Anni Tenhunen for excellent technical assistance, Transgenic, Electron Microscopy and Light Microscopy Core Facilities of Biocenter Oulu for research infrastructure services, Peppi Koivunen for the access to hypoxic chamber, Nadiya Byts for astrocyte isolation from mice brains, Gou Young Koh for COMP-ANGPT1 and Johanna Myllyharju for floxed *Egln1* mouse line. This research was supported by the Academy of Finland grants to LE (251314, 136880, 310986).

Additional information {#s5}
======================

No competing interests declared.

Conceptualization, Formal analysis, Investigation, Validation, Methodology, Visualization, Writing---original draft, Writing---review and editing.

Conceptualization, Formal analysis, Validation, Investigation, Visualization, Methodology, Writing---original draft, Writing---review and editing.

Conceptualization, Investigation, Visualization, Methodology, Writing---review and editing.

Investigation, Methodology.

Investigation, Methodology.

Investigation, Methodology.

Investigation, Methodology.

Investigation, Methodology.

Investigation, Methodology, Writing---original draft, Writing---review and editing.

Conceptualization, Formal analysis, Supervision, Funding acquisition, Validation, Investigation, Visualization, Methodology, Writing---original draft, Project administration, Writing---review and editing.

Animal experimentation: Experiments involving mice were performed under permissions from the National Animal Experiment Board following the regulations of the EU Directive 2010/63/EU, the European Convention ETS123 and national legislation. License numbers ESAVI/5587/04.10.07/2013 and ESAVI/1188/04.10.07/2016.

Additional files {#s6}
================

10.7554/eLife.37776.029

###### The sequences of primers used for quantitative RT-PCR.

10.7554/eLife.37776.030

###### The sequences of primers used for generating in situ hybridization probe template plasmids.

10.7554/eLife.37776.031

Data availability {#s7}
-----------------

All data generated or analysed during this study are included in the manuscript and supporting files.

10.7554/eLife.37776.033

Decision letter

Nathans

Jeremy

Reviewing Editor

Johns Hopkins University School of Medicine

United States

In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Angiopoietin-3-dependent venous maturation and fluid drainage in the peripheral retina\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by Jeremy Nathans as Reviewing Editor and Harry Dietz as the Senior Editor. The reviewers have opted to remain anonymous.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

As you will see, all of the reviewers were impressed with the importance and novelty of your work. Reviewer \#3 did have a major concern expressed in his point \#3 which he guessed could take more than the usual 2 months we allow for return of a revised manuscript. Please let us know if you will be able to accommodate this recommendation.

I am including the three reviews at the end of this letter, as there are a variety of specific and useful suggestions in them.

We appreciate that the reviewers\' comments cover a broad range of suggestions for improving the manuscript. Please use your best judgment in deciding which of these can be accommodated in a reasonable period of time, e.g. 2-3 months.

*Reviewer \#1:*

In this manuscript, Eklund et al. describe experiments aimed to study the function of Angiopoietin-3 (Ang3) in retinal vascular development. Using mouse Knock-in technology, they produce mouse strains that allow them to detect Ang3 expression in a subset of peripheral surface astrocytes in the developing mouse retina. Targeted deletion of Ang3 coding sequences result in loss of Ang3 expression and a specific effect on retinal peripheral veins and retinal edema. The authors also describe in vitro experiments in which the activity of mouse Ang3 and its human orthologue, Ang4, is compared to that of Ang1 and Ang2. They show that although all of these related ligands function through interactions with the Tie2 receptor, they probably interact with different affinities and dynamics that result in different functionality.

This manuscript describes a large amount of elegant work. It provides the first description of Ang3 function in retinal vasculature development and the first growth factor for venous specific development. However, the manuscript contains multiple typos, redundancies, and less than clear or accurate descriptions that will have to be addressed before publication.

Below are some specific notes.

1\) Is the peripheral retina in Ang3-/- mice hypoxic due to reduced circulation?

This could be addressed using Hypoxyprobe (pimonidazole HCl) injections or by monitoring the number of GFP positive cells in the retinas of Ang3cre/cre; Rosa26mTmG mutant mice. Hypoxia will result in increased number of GFP positive astrocytes.

2)The authors state that \"In addition, no alterations were observed in the vasculature of the intermediate or deep vascular plexus postnatally or in adults.\" but provide no data to support this assertion. How was the density of the vascular plexus measured?

3\) In the subsection "Ang3 deficiency results in neuronal edema", the authors state that they did not observe cystoid edema, inflammation, or vascular leakage. The evidence for these observations is not presented or described in any details.

4\) The first sentence of the Results section provides an inaccurate description of mouse retinal vascular development. Arteriovenous differentiation in the mouse retina occurs as the vessels grow on the retinal surface, beginning as early as P1 to P2.

5\) Redundancies: the phrase \"... human Ang4 (orthologue for mouse Ang3)....\" appears at least 3 times in the figure legends.

6\) Typos: Figure 1 legend, the sentence \"Note that Ang3 expressed cells in Ang3+/Cre; Rosa26mTmG mice....\" should read \"...Ang3 expressing cells...\" Also, the authors should add that all that GFP positive cells may just be progeny of Ang3 expressing cells.

7\) Figure 1---figure supplement 1C, the annotation Ang3;GFP for cells in which the mTmG locus has been recombined by the Ang3cre allele seems inaccurate and confusing. It is also not used anywhere else in the text.

*Reviewer \#2:*

In the manuscript entitled: Angiopoietin-3-dependent venous maturation and fluid drainage in the peripheral retina, the authors describe the generation of 3 new transgenic mouse lines targeting the Angiopoietin-4 locus and provide data on its role in activation of the tyrosine kinase receptor, Tie2 and its function in the retina. Given the importance of the angiopoietin-tie2 system, the generation of new lines targeting Angiopietin-3 is valuable. In addition, identification of venous-specific functions are intriguing and provide important new information.

A few comments for consideration by the authors are listed below:

1\) The retinal phenotype is quite subtle as shown. Do the authors have any additional functional data on flow in the retina, or neural function (e.g. ERGs etc. to support a functionally significant role of Angiopoietin-4 in the retina)?

2\) While the authors state that fluid drainage of the retina is affected by loss of Angiopoietin-4, it is not clear from the phenotype observed (i.e. smooth muscle effect or the neuron swelling) that this is due to poor drainage. The authors do comment on the absence of lymphatics in the retina and suggest that Angiopoietin-4 helps to promote drainage. Clarification of model and mechanisms involved leading to the phenotype would be helpful. As it is written, it is confusing to understand how the observed defects are related to \'retinal edema\' and fluid drainage.

3\) The smooth muscle cell phenotype is descriptive -is there anything known about potential mechanism? Is the smooth muscle phenotype only found in the periphery of veins given the expression of Angiopoietin4 in the periphery only? Also -- it is not clear how the smooth muscle cell defect relates to the enlarged HUVEC diameter in vitro -- is the effect on Tie2 in smooth muscle cells, on endos or both? Similar to comments in \#2 above, it would be helpful if the authors provided a clear model for the reader.

4\) While the Introduction talks about the importance of macula edema, it is not clear that the peripheral retinal effects would result in macula effects in humans (the location of the macula is not peripheral).

5\) A variety of different timepoints are used for specific experiments -- some rationale for choice of different timepoints would be useful.

6\) The swollen neurons and damage to Muller cells over time is nicely shown. Were rd mutations ruled out for the mouse lines under examination? Presence of rd mutations is quite common in lab mice and can affect neuron and muller function and degeneration.

7\) In the analysis of increased Angipoietin-4 expression upon PHD2 deletion -- a \'Cre only\' line control for comparison is missing in quantification.

8\) Nomenclature of Angiopoietin3 and angiopoietin4 is confusing -- official gene name in mouse is now Angiopoietin4. The authors should use the most up-to-date nomenclature.

9\) The functional studies comparing various Angiopoietins is important and a strength of the manuscript -- a western blot showing Tie2 phosphorylation should be performed to help support and quantify.

10\) The identification of a subpopulation of astrocytes is interesting. Is there anything known about the \'subpopulation\' of astrocytes expressing Angiopoietin4 -- e.g. have they been identified in other studies -- by RNAseq etc.? Is their origin known to be the same as other astrocytes?

11\) Based on structure, is there anything known about the order of oligomerization of Angiopoietin 4 to help explain its weaker agonism of Tie2?

12\) The size of the lumen appears larger after Angiopoeitin4 treatment than after Angiopietin1 treatment -- is this the case? And if so, based on weaker ability to activate Tie2 -- do the authors speculate an additional mechanism?

13\) Is angiopoeitin4 limited to retina?

14\) Is there any circulating Angiopoietin4?

*Reviewer \#3:*

This manuscript describes a remarkably specific phenotype in the retinal vasculature of Ang3 KO mice. The authors show that Ang3 is expressed by retinal astrocytes during a (so far poorly characterized) vascular remodeling event that only occurs in a specific subtype of retinal veins. The findings are interesting because they demonstrate how retinal astrocytes can contribute to retinal vasculature patterning. However, the study contains several major shortcomings.

1\) The mouse retinal vasculature initially develops as alternating artery-vein loops at the inner surface of the retina, i.e. there are the same number of veins as arteries. Subsequently, the deeper plexus develops and some of the veins are remodeled, ending up in the deeper plexus. Nevertheless, usually two veins stay at the surface, draining superficial flow. They bifurcate into a large annular vein at the peripheral edge of the retina (as indicated by Figure 2D). The authors should distinguish between these two types much more carefully throughout the manuscript in text as well as in figures.

2\) Edema/neuronal swellinga) Only the INL was assessed in Figure 5A. However, based on the location of the vein remodeling defect, one could also anticipate reduced fluid drainage in the superficial plexus, particularly in the periphery. This should also be assessed (e.g. in the IPL).

b\) It is surprising that the cellular swelling only affected the neurons and not the Müller cells (which are usually considered to be the main contributors of water drainage in the inner retina). What mechanism do the authors propose here?

c\) It is also surprising that the authors did not find evidence of interstitial edema. Wouldn\'t one expect that from a lack of venous drainage?

d\) In general, the authors should tone down their references to edema. The absence of extracellular fluid accumulation does not work well with this narrative. Furthermore, the in vivo data from the KO mice clearly points towards a vascular remodeling defect, which only secondarily leads to what may or may not be caused by reduced drainage.

3\) The second part of the paper (Figure 7/8) does not link well to the first part. Firstly, the data (shown in Figure 7/8) is too superficially explained in the Results section. Secondly, I struggle to see how this relates on a mechanistic level to the phenotypes described in the KO mice and in the in vitro lumen formation assay. Yes, the authors introduce this section with the intention to demonstrate differences between Ang1 and Ang3/4 regarding Tie2 signaling, and they do show some differences. Although, the functional readout differences are not really that impressive considering Ang3/Ang4 have much lower binding affinity to Tie2 than Ang1 (Figure 7G, H). Furthermore, I fail to see how these differences relate to expansion of venous lumen in vivo, in particular when Ang1 and Ang3/4 have a similar effect (expansion of lumen) in the in vitro lumen formation assay (Figure 6).

4\) Please indicate the age of the mice in Figure 2.

5\) A simple, second line of evidence to demonstrate oxygen-regulated Ang3 expression (Figure 2) would be exposure to hyperoxia. Why has this not been done?

6\) Please indicate the staining/visualization method in Figure 5B.

10.7554/eLife.37776.034

Author response

Reviewer \#1:

> \[...\] This manuscript describes a large amount of elegant work. It provides the first description of Ang3 function in retinal vasculature development and the first growth factor for venous specific development. However, the manuscript contains multiple typos, redundancies, and less than clear or accurate descriptions that will have to be addressed before publication.
>
> Below are some specific notes.
>
> 1\) Is the peripheral retina in Ang3-/- mice hypoxic due to reduced circulation?
>
> This could be addressed using Hypoxyprobe (pimonidazole HCl) injections or by monitoring the number of GFP positive cells in the retinas of Ang3cre/cre; Rosa26mTmG mutant mice. Hypoxia will result in increased number of GFP positive astrocytes.

Retinal hypoxia was investigated by using pimonidazole staining in whole mount preparations and measuring the mRNA expression levels of hypoxia-responsive genes *Angpt2* and *Vegfa* (Figure 7---figure supplement 1). We found no increase in these markers indicating that despite reduced venous function, retinas in *Angpt4^-/-^*mice are not hypoxic.

> 2)The authors state that \"In addition, no alterations were observed in the vasculature of the intermediate or deep vascular plexus postnatally or in adults.\" but provide no data to support this assertion. How was the density of the vascular plexus measured?

Densities of maturated vascular plexuses were calculated from histological sections (Figure 4---figure supplement 1A-C). The pattern was evaluated from confocal microscopy data in adults (Figure 4---figure supplement 1F-G) and postnatal mice (Figure 4---figure supplement 1D-E). Ultrastructure was investigated using transmission electron microscopy in adults (Figure 4---figure supplement 1H-I). Collectively, we found no consistent changes in *Angpt4*-deficient mice in the deeper vascular plexus.

> 3\) In the subsection "Ang3 deficiency results in neuronal edema", the authors state that they did not observe cystoid edema, inflammation, or vascular leakage. The evidence for these observations is not presented or described in any details.

Presence of inflammation was investigated using immunohistological staining and mRNA analysis of inflammatory markers (Figure 6---figure supplement 2). In addition to marker gene analysis, general histopathology revealed no immune cell infiltration (e.g. Figure 6A-B, Figure 4---figure supplement 1A-B).

Vascular leakage was investigated by using fluorescein angiography (new Figure 7). In our study, standard clinical imaging technology had certain limitations, as the far peripheral retina cannot be imaged by using fundus camera. Therefore, vascular leakage was also investigated using periodic acid--Schiff (PAS) stained histological sections to detect hard exudates that are formed due to leakage of serum protein and lipids. Evidence for vascular leakage in PAS staining was not observed, negative result is shown in Figure 4---figure supplement 1A-B. In line with results of fluorescein angiography and PAS staining, distribution of fluorospheres (co-injected with Evans blue, a serum albumin-bound intravital dye for vascular permeability) was not suggestive for leakage (Figure 7F-G).

In cystoid edema, fluid-filled cysts disrupt the structure of retinal layers and are readily apparent in microscopy. In histological analysis (light/electron microscopy) we found no evidence for presence of alterations suggestive for cystoid edema (e.g. Figure 6A-B, Figure 4---figure supplement 1A-B and Figure 6---figure supplement 1).

> 4\) The first sentence of the Results section provides an inaccurate description of mouse retinal vascular development. Arteriovenous differentiation in the mouse retina occurs as the vessels grow on the retinal surface, beginning as early as P1 to P2.

We have added new reference and corrected text accordingly.

> 5\) Redundancies: the phrase \"... human Ang4 (orthologue for mouse Ang3)....\" appears at least 3 times in the figure legends.

Nomenclature is now corrected based on gene naming guidelines of the HUGO Gene Nomenclature Committee and the Mouse Genome Informatics. Mouse Ang3 gene is now named as *Angpt4* and protein Angpt4. Human gene is now named as *ANGPT4* and protein ANGPT4.

> 6\) Typos: Figure 1 legend, the sentence \"Note that Ang3 expressed cells in Ang3+/Cre; Rosa26mTmG mice....\" should read \"...Ang3 expressing cells...\" Also, the authors should add that all that GFP positive cells may just be progeny of Ang3 expressing cells.

This is now corrected.

> 7\) Figure 1---figure supplement 1C, the annotation Ang3;GFP for cells in which the mTmG locus has been recombined by the Ang3cre allele seems inaccurate and confusing. It is also not used anywhere else in the text.

This is now corrected.

Reviewer \#2:

> \[...\] A few comments for consideration by the authors are listed below:
>
> 1\) The retinal phenotype is quite subtle as shown. Do the authors have any additional functional data on flow in the retina, or neural function (e.g. ERGs etc. to support a functionally significant role of Angiopoietin-4 in the retina)?

Venous filling is now investigated in fluorescein angiography (FA) and using injection of fluorescent microbeads to carotid artery that supplies the blood to the ophthalmic artery. The latter approach allowed us to focus on peripheral retina that is limited in the standard FA imaging using fundus camera. In both analysis, venous flow was found to be impaired in Angpt4-deficient mice (new Figure 7).

In *Angpt4*^-/-^ mice electroretinogram (fERG) was used to measure light-induced electrical activity of the retina. We found reduction in b-wave amplitude that reflects the function of non-photoreceptors including bipolar, amacrine, and Müller cells, thus correlating with the cellular changes in the INL layer (Figure 7I).

> 2\) While the authors state that fluid drainage of the retina is affected by loss of Angiopoietin-4, it is not clear from the phenotype observed (i.e. smooth muscle effect or the neuron swelling) that this is due to poor drainage. The authors do comment on the absence of lymphatics in the retina and suggest that Angiopoietin-4 helps to promote drainage. Clarification of model and mechanisms involved leading to the phenotype would be helpful. As it is written, it is confusing to understand how the observed defects are related to \'retinal edema\' and fluid drainage.

In *Angpt4*-deficient mice, we observe defective circumferential growth of veins. Based on Poiseuille\'s equation, vessel flow is proportional to its radius. In line with this suggestion, functional tests using fluorescent tracers showed decreased venous function in *Angpt4*^-/-^ mice (Figure 7F-H). We propose that smooth muscle defect occurs independently from decreased venous flow as it is evident earlier than peripheral venous circulation is fully established. Alterations in neural cells are not visible in postnatal mice but appear later, suggesting that structural and functional changes in the INL occur secondary to defective venous flow and reduced venous-dependent fluid exit mechanisms. A graphical summary to clarify the model and mechanisms involved is now presented in new Figure 11.

> 3\) The smooth muscle cell phenotype is descriptive -is there anything known about potential mechanism?

Using definite markers for SMC maturation (αSMA, SM22, myofilament structures and fibrillar collagen matrix) in different developmental stages, we demonstrate that Angpt4 is required for retinal vein SMC maturation in vivo. A limitation of our work is that we could not dissect the whole molecular pathway how Angpt4 induces SMC maturation starting from Angpt4 producing astrocytes and ending to the expression of SMCs maturation markers. In-depth in vitro mechanistical studies were hindered by the lack of SMC precursor cells and tissue culturing model that could faithfully represent SMC maturation that occurs in the retina involving endothelial cells and astrocytes.

To mechanistically better understand Angpt4 signaling pathway in vivo, we have now investigated the expression of Angpt4 receptor Tie2, as well as Angpt1 and Angpt2 in the peripheral retina at the time of venous maturation (new Figure 3A-E). Based on close location of Angpt4-expressing astrocytes to both SMCs and ECs, we consider two signaling mechanisms possible, either 1) directly from astrocytes to SMCs or 2) to SMCs via EC-produced factor. Previous studies have indicated Angpt4 receptor Tie2 expression preferentially in EC, but also in some SMC precursor cells (Iurlaro et al., J Cell Sci. 2003, 116:3635-3643). In in situ hybridization experiments, however, we found Tie2 mRNAs only in ECs (new Figure 3E). Therefore, direct signaling from astrocytes to SMCs is not likely.

> Is the smooth muscle phenotype only found in the periphery of veins given the expression of Angiopoietin4 in the periphery only?

To address this question exhaustively, we investigated Angpt4 spatiotemporal expression using *in situ* hybridization in additional (earlier) developmental stages and analyzed venous αSMA expression and diameters close to optic nerve head (new panels in Figure 4, and new Figure 3). These analyses verified enhanced Angpt4 expression in the peripheral retina at P12, as we observed in genetic models. At P3 (the earliest time point we found consistent Angpt4 expression), Angpt4 was expressed in astrocytes preceding the vascular front in the mid- to peripheral retina. In contrast, Angpt4 was not expressed in central retina near to the optic nerve head (Figure 3A). In central retina, venous SMCs were not affected, thus confirming the spatial correlation of the SMC phenotype in *Angpt4*^-/-^ mice with Angpt4 expression in WT mice.

> Also -- it is not clear how the smooth muscle cell defect relates to the enlarged HUVEC diameter in vitro -- is the effect on Tie2 in smooth muscle cells, on endos or both?

To investigate more carefully the Angpt4 signaling pathway involving ECs, SMCs and possible signaling loops between these cells, we analyzed Angpt4 receptor Tie2 expression in the retina and effects of Angpt4 in single and co-culture models of ECs and SMCs. We show that in the developing retina, Tie2 is expressed in ECs and not in SMCs (new Figure 3E). This suggested a model in which Angpt4 stimulates SMC maturation via ECs, rather than direct signaling from astrocytes to SMCs. This is in line with the results that in fibrin gel spheroid model, Angpt4-induced lumen enlargement is not enhanced by SMCs (Figure 8---figure supplement 1A), and that in single SMC culture Angpt4 did not affect SMC proliferation, survival, migration or stimulated SMC spheroids (Figure 5---figure supplement 1A-C and Figure 8---figure supplement 1B). As pointed out above, it is noteworthy that direct comparison between in vivophenotype and in vitro experiments is difficult, since currently SMC precursor cells and tissue culturing models to faithfully represent venous SMC maturation in the retina are lacking.

> Similar to comments in \#2 above, it would be helpful if the authors provided a clear model for the reader.

Based on new datawe proposed a model (a graphical summary in Figure 11) in which Angpt4 is produced by astrocytes, and signals via Tie2/Akt to ECs to promote venous remodeling. In *Angpt4*^-/-^ mice, venous growth and SMC maturation are defective, resulting in reduced flow, impaired fluid clearance and secondary cellular and functional defects in neuronal retina.

> 4\) While the Introduction talks about the importance of macula edema, it is not clear that the peripheral retinal effects would result in macula effects in humans (the location of the macula is not peripheral).

Based on clinical findings, the macula can be predisposed to edema even if primary defect is peripheral retina. This is now included in the Discussion.

> 5\) A variety of different timepoints are used for specific experiments -- some rationale for choice of different timepoints would be useful.

Time points were selected based on previous knowledge regarding phases of venous development and published phenotypes in Angpt1 and Angpt2 deficient mice for comparison. Two months old mice were considered as adults (fully maturated) and aged mice were 8-11 months to investigate possible progression of retinal pathologies. This is now included in the Materials and methods section.

> 6\) The swollen neurons and damage to Muller cells over time is nicely shown. Were rd mutations ruled out for the mouse lines under examination? Presence of rd mutations is quite common in lab mice and can affect neuron and muller function and degeneration.

*Angpt4* gene targeting was done in ES cells from C57BL/6N strain. Founder mice were crossed with ACTB-FLPe in C57BL/6J sub-strain to remove Frt-flanked neo selection gene from targeted *Angpt4* allele. Resulting *Angpt4* heterozygous mice (F1 6N /6J hybrid background) were crossed with each other to generate *Angpt4*^-/-^ and sibling control mice and were also backcrossed to C57BL/6N.

6N (but not 6J) sub-strain carries spontaneous rd8/rd8 mutation in the gene encoding *Crb1* that is normally locatedat the outer limiting membrane of the retina. Pathologies are observed *in* the outer retinal layer, including variable number of local light-colored spots due to retinal folding and slow photoreceptor loss. Pseudorosettes are apparent in histological analysis, and Müller and microglia activation and telangiectasia-like vascular lesions are reported close to the sites of retinal degeneration (Luhmann et al., Human Molecular Genetics, 2015, 24: 128-1241; Mehalow et al., Hum. Mol. Genet. 2003, 12:2179--2189; Mattapallil et al., Invest Ophthalmol Vis Sci. 2012, 53:2921-2927). Presence of rd8 mutation was detected by sequencing in our mouse colony. As expected, in mice backcrossed to C57BL/6N sub-strain, homozygous rd8/rd8 was present in all *Angpt4*^-/-^ and *Angpt4*^+/+^ mice. In 6N /6J hybrid background (F2 generation) rd8 was either present or absence in *Angpt4* deficient and control mice, that allowed us to evaluate possible effects of rd8 mutation in *Angpt4*^-/-^; Crb1^rd8/rd8^, *Angpt4*^-/-^; Crb1^+/+^, *Angpt4*^+/+^; Crb1^rd8/rd8^, and *Angpt4*^+/+^; Crb1^+/+^ genotypes. We conclude that Angpt4 and Crb1 loci are in different chromosomes (genetically not linked), rd8 and *Angpt4*^-/-^ phenotypes are clearly distinct, Angpt4 and Crb1 proteins in WT and phenotypes in deficient mice are located in the different part of retina, and that the observed phenotypes in *Angpt4*^-/-^mice are not caused or influenced by the *rd8* mutation.

> 7\) In the analysis of increased Angipoietin-4 expression upon PHD2 deletion -- a \'Cre only\' line control for comparison is missing in quantification.

In Figure 2H, we compare *Angpt4* expression between *Angpt4*^+/+^; *Egln1*^loxP/loxP^ (*Phd2* is now named according its approved gene name *Egln1*) and *Angpt4*^+/Cre^; *Egln1*^loxP/loxP^ mice. In *Angpt4*^+/Cre^; *Egln1*^loxP/loxP^ mice, only one functional *Angpt4* allele remains and this has been taken into account when fold change is calculated.

In \'Cre only\' i.e. *Angpt4*^Cre/Cre^, mRNAs for *Angpt4* are not transcribed (Figure 1---figure supplement 1D).

After revision was invited, we started to breed mice so that we could include P12 *Angpt4*^+/Cre^; *Egln1*^+/+^ as an additional control. Unfortunately, we failed to get litters containing necessary genotypes for comparison: *Angpt4*^+/Cre^; *Egln1*^+/+^ and *Angpt4*^+/+^; *Egln1*^loxP/loxP^ and *Angpt4*^+/Cre^; *Egln1*^loxP/loxP^.

> 8\) Nomenclature of Angiopoietin3 and angiopoietin4 is confusing -- official gene name in mouse is now Angiopoietin4. The authors should use the most up-to-date nomenclature.

In the revised manuscript, nomenclature is corrected based on gene naming guidelines of the HUGO Gene Nomenclature Committee and the Mouse Genome Informatics. This is also indicated in the Materials and methods section.

Mouse Ang3 gene is now named as *Angpt4* and protein Angpt4. Human gene is now named as *ANGPT4* and protein ANGPT4.

> 9\) The functional studies comparing various Angiopoietins is important and a strength of the manuscript -- a western blot showing Tie2 phosphorylation should be performed to help support and quantify.

We now show TIE2 tyrosine phosphorylation usingimmunoprecipitation and Western blot analysis (new Figure 9---figure supplement 2). Stimulation time was same than in immunofluorescence staining (Figure 9A) and TIE2 activation potency of mouse Angpt4 and human ANGPT4 was compared to native ANGPT1 (natural agonistic ligand), COMP-ANGPT1 (designed agonistic ligand), and Angpt2 (context-dependent antagonist/low agonist). As previously published (Lee et al., 2004), mouse Angpt4 showed a species-specific effect as it induced relatively low TIE2 tyrosine phosphorylation in human ECs when total TIE2 proteins were analyzed in WB. As shown in Figure 9A, TIE2 activation is observed in Angpt4-stimulated HUVECs as a punctuate staining specially in EC-EC junctions while a vast majority of TIE2 is evenly located on plasma membrane and not activated (negative for immunostaining for phosphorylated Tyr992 on the kinase *activation loop*). We have validated earlier the specificity of used antibody; it detects angiopoietin-stimulated TIE2-WT and over-activating TIE2-L914F mutation but does not stain TIE2 with kinase-inactivating mutation K855R (Nätynki et al., 2015). In Angpt4-stimulated HUVECs, fraction of cell-cell junction translocated and activated TIE2 is relatively small and may not be easily debatable in WB, nevertheless it is sufficient to stimulate lumen formation in a spheroid assay (Figure 8A-B). Why human ANGPT4 is more potent than mouse Angpt4 to induce TIE2 activation in human ECs is currently not known, but it may relate to lower oligomerization state of Angpt4 (Figure 9---figure supplement 2C-D).

> 10\) The identification of a subpopulation of astrocytes is interesting. Is there anything known about the \'subpopulation\' of astrocytes expressing Angiopoietin4 -- e.g. have they been identified in other studies -- by RNAseq etc.? Is their origin known to be the same as other astrocytes?

To best of our knowledge, Angpt4 expression has not been identified in retinal astrocytes earlier. This is likely due to lack of suitable tools to pick up relatively rare population of Angpt4 positive cells among all astrocytes. It is also currently unknown if their origin is the same as other astrocytes. The tools we have generated in this study allow isolation and characterization of Angpt4 positive astrocytes. In-depth investigation of origin, specific characteristics and importance of Angpt4 positive astrocytes requires extensive additional experiments and will be focused on in another study.

> 11\) Based on structure, is there anything known about the order of oligomerization of Angiopoietin 4 to help explain its weaker agonism of Tie2?

We have now compared purified recombinant angiopoietin proteins used in this study in reducing and non-reducing conditions in SDS-PAGEs and Western blots (new Figure 9---figure supplement 2C-D). As expected based on previous studies, ANGPT1 formed various-sized large oligomeric/multimeric complexes, ANGPT2 ran predominantly as disulfide-linked dimers, Angpt4 showed monomeric, dimeric and some larger complexes, and ANGPT4 dimeric and higher oligomeric /multimeric ligand complexes. Interestingly, mouse Angpt4 was less potent to induce TIE2 activation in WB and this may relate to lower oligomerization state of Angpt4 (Figure 9---figure supplement 2A-D). This is now included in the Results.

> 12\) The size of the lumen appears larger after Angiopoeitin4 treatment than after Angiopietin1 treatment -- is this the case? And if so, based on weaker ability to activate Tie2 -- do the authors speculate an additional mechanism?

In ANOVA (as in Figure 8A) or in t-test, Angiopoietin-4 and Angiopoietin-1 -induced lumen sizes are not different.

"do the authors speculate an additional mechanism?": Comparison of angiopoietins has revealed that Angpt4, but not other angiopoietins, is tethered on the cell surface via heparan sulfate proteoglycans that is required for bioactivity of Angpt4 (Xu et al., J Biol Chem. 2004, 279: 41179--41188). We show here that Angpt4 and Angpt4 are not ECM bound like ANGPT1 and do not promote TIE2 translocation into EC-ECM contact sites that previously have shown to preferentially activate Erk signaling (Saharinen et al., 2008; Fukuhara et al., 2008). Differential ECM binding we found in this study may alter TIE2 signaling and bioavailability of ligands.

> 13\) Is angiopoeitin4 limited to retina?

In this study, we primarily focused on retina as a widely used model for angiogenic growth, remodeling and maturation. As the neural retina can be considered as a part of central nervous system (CNS), we were also interested in whether Angpt4 expressing astrocytes are also present in the brains. To support this suggestion, ANGPT4 protein was reported to be expressed in normal, unselected population of human astrocytes at low level and increased in human glioma (Brunckhorst et al., 2010). However, in mouse brain astrocyte cultures we did not find Angpt4 expression (new Figure 10---figure supplement 1A). Astrocytes are known to be heterogeneous cells, and these results further strengthen our conclusion that Angpt4^+^ astrocytes represent a specific subpopulation among the glial cells.

To investigate non-central nervous tissue, we have now analyzed mesenteric whole-mounts, where vasculature is readily visible for microscopic analysis. Interestingly, Angpt4 expression was found in arterial SMCs (new Figure 10).

Negative result (no expression in brain astrocytes) and expression in certain SMCs are in line with a recent comprehensive single-cell transcriptomic study of the mouse brain vasculature (Vanlandewijck et al., 2008). Furthermore, Angpt1-GFP is reported to be expressed in the neuronal cells at P5 in mouse retina, but also in perivascular mural cells in choroidal vessels. The data is currently somewhat limited but suggests that in non-retinal tissue expression of Angpt1 and Angpt4 may be overlapping in some perivascular mural cells. This raises interesting questions regarding specific/synergistic/additional effects of these Tie2-agonistic ligands in non-CNS tissues that will be addressed in subsequent studies.

> 14\) Is there any circulating Angiopoietin4?

The presence of Angpt4 was invested in P12 serum using commercially available ELISA. Based on this assay, there is no detectable Angpt4 in mouse sera (new Figure 10---figure supplement 1B). In addition, amount of soluble Angpt4 in eye preparation was relatively low.

Reviewer \#3:

> This manuscript describes a remarkably specific phenotype in the retinal vasculature of Ang3 KO mice. The authors show that Ang3 is expressed by retinal astrocytes during a (so far poorly characterized) vascular remodeling event that only occurs in a specific subtype of retinal veins. The findings are interesting because they demonstrate how retinal astrocytes can contribute to retinal vasculature patterning. However, the study contains several major shortcomings.
>
> 1\) The mouse retinal vasculature initially develops as alternating artery-vein loops at the inner surface of the retina, i.e. there are the same number of veins as arteries. Subsequently, the deeper plexus develops and some of the veins are remodeled, ending up in the deeper plexus. Nevertheless, usually two veins stay at the surface, draining superficial flow. They bifurcate into a large annular vein at the peripheral edge of the retina (as indicated by Figure 2D). The authors should distinguish between these two types much more carefully throughout the manuscript in text as well as in figures.

In whole mounts, these two vein types were distinguished based on presence or absence of connection to the large annular vein at the peripheral retina. Most analysis were done close to bifurcation site of the large annular vein and ora serrata. In histological sections, we focused on far peripheral region of retina so that peripheral and paracentral veins were not mixed. Exceptions are Figure 7 (due to limited field of view in fluorescein angiography only shortest veins were excluded, analysis may contain few veins that are extended to more periphery but not connected to annular vein in the far periphery) and Figure 4H and K (all centrally located veins were included for comparison vs. peripheral veins). Different types of veins (peripheral annular and central/paracentral) are now distinguished in the figures whenever possible.

> 2\) Edema/neuronal swellinga) Only the INL was assessed in Figure 5A. However, based on the location of the vein remodeling defect, one could also anticipate reduced fluid drainage in the superficial plexus, particularly in the periphery. This should also be assessed (e.g. in the IPL).

We have now carefully analyzed additional retinal layers (Figure 6---figure supplement 1). Ultrastructural changes suggestive for neuronal cell swelling (increased volume of cell organelle free cytoplasm, disordered cellular organization) were observed in the INL, but not in other retinal layers. Defective vein development in *Angpt4*^-/-^ mice shares some similarities with retinal vein occlusions (RVO) (i.e. reduced venous drainage) but is less severe and does not result in inflammation or leakage that further increases excessive fluid in RVO. In the peripheral retina Angpt4 receptor Tie2 is expressed only in endothelial cells (new Figure 3E), suggesting that direct Angpt4 signaling from astrocytes to neuronal cells is unlikely. Furthermore, we observe alterations in the INL in mature eye after venous remodeling defect and high Angpt4 expression at P12. Based on our data, we propose that ultrastructural changes in the INL are secondary to reduced vein function. Distance between the superficial vasculature and the INL is about 50 μm (roughly equals with the average distance between capillaries in the retina). Functional venous flow may be especially important for INL, while diffusion to the vitreous in the most superficial layer and pigment epithelial cell pumps in outer layer may provide additional/compensatory mechanisms. Schematic model is presented in new Figure 11.

> b\) It is surprising that the cellular swelling only affected the neurons and not the Müller cells (which are usually considered to be the main contributors of water drainage in the inner retina). What mechanism do the authors propose here?

In electron microscopic analysis of INL, we observe changes in the normal architecture of Müller cells (discontinuation of Müller cell processes)that normallyspan across the retina, but no increase in Müller cell volume. Swelling of Müller cells occur in retinal pathologies and associated altered expression of AQP4 water or Kir4.1 potassium channel in Müller cells that may result in dysfunctional water homeostasis in these cells. In *Angpt4*^-/-^ retinas, we found no changes in AQP4 nor Kir4.1, suggesting that water balance in Müller cells may be retained. Neuronal cells (amacrine and bipolar cells in the INL), may lack efficient water transport mechanism and be more vulnerable for alterations in fluid homeostasis due to diminished venous drainage. This can be aggravated by the alterations in Müller cell architecture. This assumption is now included in Discussion.

> c\) It is also surprising that the authors did not find evidence of interstitial edema. Wouldn\'t one expect that from a lack of venous drainage?

In the revised manuscript, we investigated the severity of venous dysfunction in *Angpt4*^-/-^ retinas. In fundus angiography, venous filling is slower in *Angpt4*^-/-^ mice and carotid artery injected fluorospheres accumulated in the peripheral annular vein in the *Angpt4*^-/-^ mice (new Figure 7). Based on these functional assays, venous drainage is impaired, but not completely blocked. As also pointed above, in literature we found no similar pathology than we observe in *Angpt4*^-/-^ mice (i.e. decrease in vein diameter, diminished peripheral vein flow, venous SMC abnormality, no inflammation, no leakage), making direct comparison to other retinal vascular pathologies (i.e. diabetic retinopathy, retinal vein occlusion) difficult. It may be possible that interstitial edema is prominent in vascular diseases in which vascular barrier disrupted, which causes large increase in fluid entry that is excessive for exit mechanisms. Those neuronal cells that lack efficient water pumping mechanism may make them more vulnerable for passive influx of fluid that may be increased in *Angpt4*^-/-^ retinas. This is now discussed.

> d\) In general, the authors should tone down their references to edema. The absence of extracellular fluid accumulation does not work well with this narrative. Furthermore, the in vivo data from the KO mice clearly points towards a vascular remodeling defect, which only secondarily leads to what may or may not be caused by reduced drainage.

This is done. In *Angpt4*^-/-^ mice, we first observe venous remodeling defect in postnatal mice and we propose that other phenotypes (impaired venous drainage and neuronal cell changes) are secondary. The model is now presented in schematic summary (new Figure 11).

> 3\) The second part of the paper (Figure 7/8) does not link well to the first part. Firstly, the data (shown in Figure 7/8) is too superficially explained in the Results section. Secondly, I struggle to see how this relates on a mechanistic level to the phenotypes described in the KO mice and in the in vitro lumen formation assay. Yes, the authors introduce this section with the intention to demonstrate differences between Ang1 and Ang3/4 regarding Tie2 signaling, and they do show some differences. Although, the functional readout differences are not really that impressive considering Ang3/Ang4 have much lower binding affinity to Tie2 than Ang1 (Figure 7G, H). Furthermore, I fail to see how these differences relate to expansion of venous lumen in vivo, in particular when Ang1 and Ang3/4 have a similar effect (expansion of lumen) in the in vitro lumen formation assay (Figure 6).

In *Angpt4*^-/-^ mice, we observed venous SMCs abnormality and smaller diameter of annular veins. Possible molecular and cellular pathway by which Angpt4 may promote luminal growth and EC to SMC signaling were investigated in vitro either as single cell type or in co-culture models. Another motivation for detailed in vitro comparison of angiopoietins was that it has been controversial how well human and mouse Angpt4functions are conserved due to divergence in their primary structures. Reviewer 2 foundstudies comparing angiopoietins important and strengthening the manuscript. In addition, we were also requested for some additional in vitro comparisons of angiopoietins that we have faithfully done (Figure 9---figure supplement 2). Please find below, how in vitro and in vivo experiments are linked together, and how in vitro experiments help mechanistically understand in vivo results. Also, the data is now explained more extensively in the Results section.

Tie2 is mainly expressed in ECs, however, its expression is also reported in vascular mural cell precursors (Iurlaro et al., J Cell Sci. 2003, 116:3635-3643), and therefore we considered it possible that astrocytes may directly signal to SMCs. In line with this suggestion we found some TIE2 expression in SMC lines isolated from maturated veins and arteries (Figure 5K). Excesses of ANGPT4, however, had no effect on SMCs cellular functions (proliferation, migration, survival) (Figure 5---figure supplement 1).

As SMC lines isolated form maturated veins may not well represent SMC precursor cells in the developing retina, we further investigated Angpt4 receptor *Tie2* mRNA expression in retinas using in situ hybridization at P12, when Angpt4 expression is high and venous remodeling of large annular vein occurs. As shown in new Figure 3E, *Tie2* expression is detected only in ECs in peripheral retina. Collectively, based on in vitro and in vivo data, direct Angpt4 signaling from astrocytes to SMCs via Tie2 is not likely.

Possible molecular pathway by which ANGPT4 may increase expansion of luminal structure was investigated in fibrin gel model, either using ECs alone or co-culture model of EC/SMC spheroids (Figure 8 and new Figure 8---figure supplement 1A). ANGPT4 and Angpt4 expanded lumen structure in ECs and addition of SMCs had no effect, also proposing that ANGPT4 and Angpt4 may primarily signal to ECs via TIE2. In line with this suggestion, TIE2 shRNA silenced HUVECs did not respond to ANGPTt4 in a spheroid assay, indicating the dependence of endothelial TIE2 in expansion of luminal structure in vitro.

Comparison of ANGPT1, Angpt4 and ANGPT4 in the spheroid assay revealed that despite their divergent primary structures and differences in biochemical properties, we found that they all are competent to increase luminal structure via the same signaling pathway. In addition, careful analysis of EC-EC junctions revealed that they all activated TIE2 in this specific subcellular compartment that is important for TIE2/AKT signaling (Saharinen et al., 2008; Fukuhara et al., 2008). These results suggest that functions of ANGPT1, Angpt4 and ANGPT4 are partly conserved. This is in line with a previous study in mouse, in which excess of these ligands similarly induced blood and lymphatic vascular remodeling (Kim et al., 2007).

In the far peripheral retina, Angpt2 and Angpt4 (new Figure 3) were both expressed at P12 when venous maturation occurred in this domain. in vitro, ANGPT2 did not induce TIE2 activation in EC-EC junctions and did not enhance lumen formation, indicating that ANGPT2 less potent to functionally compensate ANGPT4 to promote venous growth, thus partly explaining specific phenotype in Angpt4 deficient mice.

Collectively, combination of in vitro and in vivo results suggested a model in which Angpt4 primarily signals via endothelial Tie2 to enhance EC to SMC signaling for SMCs maturation (new Figure 11). The previously observed vascular phenotype in Angpt4 deficient retinas was clearly different from that observed in mice lacking Angpt1 or Angpt2 and based on our data we propose that differentially regulated expression of angiopoietins is an important mechanism to generate ligand-specific functions in the developing eye.

ANGPT1 is an obligatory agonistic ligand and binds to TIE2 with a high affinity (Kd 3.7 nM, Davis et al., Cell, 1996, 8:1161--1169). We show that although binding affinity of human ANGPT4 to TIE2 is lower, it is still sufficient for TIE2 activation in Western blot and in cell-cell junctions. In this specific compartment, also mouse Angpt4 activated human TIE2.

> 4\) Please indicate the age of the mice in Figure 2.

This is done.

> 5\) A simple, second line of evidence to demonstrate oxygen-regulated Ang3 expression (Figure 2) would be exposure to hyperoxia. Why has this not been done?

We were originally interested in ischemia that is considered to be more relevant for many vascular diseases. *Angpt4* gene promoter contains hypoxia response element and based on our data we are confident that *Angpt4* expression in positively regulated by low oxygen. Nevertheless, hyperoxia experiment is now done; WT and *Angpt4*^Cre^ ; *Rosa*26^mTmG^ mice were placed in a 75% oxygen chamber for 5 days and euthanized at P12 together with control mice that were raised under normoxic conditions. As shown in new Figure 2---figure supplement 2, *Angpt1* mRNA expression was decreased while *Angpt2* and *Angpt4* increased. In addition, there was a trend for increased number of *Angpt4*^+^ astrocytes. The results are not straightforward to interpret as raising newborn mice in hyperoxia may not be a simple negative control for hypoxia: Hyperoxia has reported to paradoxically cause retinal hypoxia by blocking vascular development (West et al., Development, 2005) that may perhaps explain increase in *Angpt2* and *Angpt4* expression. In addition, hyperoxia has toxic effects in the retina causing retinal degeneration (Yamada et al., J Cell Physiol. 1999) and it may be possible that increase in *Angpt4* may relate to more general stress reaction in the retina. Finally, a short-term hyperoxia promotes astrocytic differentiation (Duan et al., Sci Reports, 2017) and may also affect *Angpt4*^+^ astrocytes. In addition to hypoxia, other mechanism to regulate *Angpt4* expression also likely exists.

> 6\) Please indicate the staining/visualization method in Figure 5B.

This is now done.

[^1]: These authors contributed equally to this work.
